{
  "meta": {
    "id": "test31",
    "title": "Mid Day Module (Medicine-2) - 2024-12-08",
    "category": "Subject Wise / Mixed"
  },
  "questions": [
    {
      "text": "Which of the following is NOT used for the treatment of HIV-associated lipodystrophy?",
      "options": [
        {
          "label": "A",
          "text": "Metformin",
          "correct": false
        },
        {
          "label": "B",
          "text": "Pioglitazone",
          "correct": false
        },
        {
          "label": "C",
          "text": "Tesamorelin",
          "correct": false
        },
        {
          "label": "D",
          "text": "Metreleptin",
          "correct": true
        }
      ],
      "correct_answer": "D. Metreleptin",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Metreleptin</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Metformin: Can reduce abdominal fat in HALS.</li><li>\u2022 Option A. Metformin:</li><li>\u2022 Option B. Pioglitazone: Can be used to treat lipoatrophy and hepatic steatosis in HALS.</li><li>\u2022 Option B. Pioglitazone:</li><li>\u2022 Option C. Tesamorelin: A growth hormone-releasing hormone analog that helps reduce excess abdominal fat in HALS (but IGF-1 should be monitored).</li><li>\u2022 Option C. Tesamorelin:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Metreleptin is used to treat generalized lipodystrophy and is not specifically used for HIV-associated lipodystrophy.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "68ee8eca",
      "audio": ""
    },
    {
      "text": "A young woman with type 1 diabetes presents to the emergency department with diabetic ketoacidosis (DKA) after stopping insulin. On examination, she is delirious and initial laboratory reports show: S. Na 128 mEq/L, S. K+ 4.3 mEq/L, BUN 76 mg/dL, S. Cr 2.2 mg/dL, S. HCO3- 10 mEq/L, Blood glucose 520 mg/dL. Which of the following is NOT an appropriate treatment?",
      "options": [
        {
          "label": "A",
          "text": "3% NaCl",
          "correct": true
        },
        {
          "label": "B",
          "text": "IV fluids",
          "correct": false
        },
        {
          "label": "C",
          "text": "Insulin infusion",
          "correct": false
        },
        {
          "label": "D",
          "text": "Potassium supplementation",
          "correct": false
        }
      ],
      "correct_answer": "A. 3% NaCl",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) 3% NaCl</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. 0.9% sodium chloride (NaCl): This isotonic fluid is appropriate for rehydration in DKA.</li><li>\u2022 Option B. 0.9% sodium chloride (NaCl):</li><li>\u2022 Option C. Insulin infusion: This is essential to lower blood glucose levels and correct ketoacidosis in DKA.</li><li>\u2022 Option C. Insulin infusion:</li><li>\u2022 Option D. Potassium supplementation: While initial potassium levels are normal, they can drop rapidly with insulin therapy. Therefore, potassium supplementation is often necessary during DKA treatment.</li><li>\u2022 Option D. Potassium supplementation:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Hypertonic saline (3% NaCl) is not indicated in DKA with pseudohyponatremia; it could worsen the hyperosmolar state.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "0f768713",
      "audio": ""
    },
    {
      "text": "A 54-year-old man with long-standing diabetes presents with the lesion shown in the image. Identify the condition:",
      "options": [
        {
          "label": "A",
          "text": "Diabetic dermopathy",
          "correct": true
        },
        {
          "label": "B",
          "text": "Necrobiosis lipoidica diabeticorum",
          "correct": false
        },
        {
          "label": "C",
          "text": "Lichen planus",
          "correct": false
        },
        {
          "label": "D",
          "text": "Scleredema",
          "correct": false
        }
      ],
      "correct_answer": "A. Diabetic dermopathy",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/20/screenshot-2024-08-20-093055.png"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Diabetic dermopathy</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Necrobiosis lipoidica diabeticorum: This condition presents as larger, yellowish-brown patches with a raised, reddish border, often located on the shins.</li><li>\u2022 Option B. Necrobiosis lipoidica diabeticorum:</li><li>\u2022 Option C. Lichen planus: This inflammatory skin condition presents as purple, itchy, flat-topped bumps.</li><li>\u2022 Option C. Lichen planus:</li><li>\u2022 Option D. Scleredema: This condition is characterized by thickening and hardening of the skin, usually on the back or neck.</li><li>\u2022 Option D. Scleredema:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Diabetic dermopathy, characterized by hyperpigmented atrophic macules over the shins, is the most common cutaneous manifestation of diabetes.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "fab0f4a0",
      "audio": ""
    },
    {
      "text": "A 50-year-old patient with newly diagnosed type 2 diabetes mellitus (T2DM) has a negative urine microalbumin test. When should the next urine microalbumin test be repeated?",
      "options": [
        {
          "label": "A",
          "text": "In 3 months",
          "correct": false
        },
        {
          "label": "B",
          "text": "In 6 months",
          "correct": false
        },
        {
          "label": "C",
          "text": "In 1 year",
          "correct": true
        },
        {
          "label": "D",
          "text": "In 5 years",
          "correct": false
        }
      ],
      "correct_answer": "C. In 1 year",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/20/screenshot-2024-08-20-094813.png"
      ],
      "explanation": "<p><strong>Ans. C) In 1 year</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 Option A. In 3 months: Too frequent for routine screening and not necessary with a negative initial test.</li><li>\u2022 Option A. In 3 months:</li><li>\u2022 Option B. In 6 months: While more frequent screening may be indicated in some cases, annual testing is generally sufficient for initial monitoring.</li><li>\u2022 Option B. In 6 months:</li><li>\u2022 Option D. In 5 years: Too infrequent for monitoring diabetic nephropathy, as significant damage could occur undetected in this time frame.</li><li>\u2022 Option D. In 5 years:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Annual screening for microalbuminuria is recommended in type 2 diabetes to detect early signs of diabetic nephropathy.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "0bbe25bc",
      "audio": ""
    },
    {
      "text": "A 45-year-old man with type 2 diabetes presents to the emergency department with DKA. His initial blood glucose level is 650 mg/dL. After 6 hours of treatment with intravenous fluids and insulin, his blood glucose drops to 200 mg/dL. Which of the following is the most appropriate next step in management?",
      "options": [
        {
          "label": "A",
          "text": "Discontinue the insulin infusion",
          "correct": false
        },
        {
          "label": "B",
          "text": "Switch to subcutaneous insulin",
          "correct": false
        },
        {
          "label": "C",
          "text": "Add dextrose to the intravenous fluids",
          "correct": true
        },
        {
          "label": "D",
          "text": "Increase the rate of the insulin infusion",
          "correct": false
        }
      ],
      "correct_answer": "C. Add dextrose to the intravenous fluids",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Add dextrose to the intravenous fluids</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Discontinue the insulin infusion: Insulin should not be discontinued until the ketoacidosis is resolved, as indicated by a normal anion gap and beta-hydroxybutyrate level.</li><li>\u2022 Option A. Discontinue the insulin infusion:</li><li>\u2022 Option B. Switch to subcutaneous insulin: Subcutaneous insulin is not appropriate in the acute management of DKA.</li><li>\u2022 Option B. Switch to subcutaneous insulin:</li><li>\u2022 Option D. Increase the rate of the insulin infusion: Increasing the insulin infusion rate could lead to hypoglycemia.</li><li>\u2022 Option D. Increase the rate of the insulin infusion:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 When blood glucose drops to 200-250 mg/dL during DKA treatment, add dextrose to IV fluids to prevent hypoglycemia and continue insulin infusion.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "fbb895fd",
      "audio": ""
    },
    {
      "text": "A 17-year-old boy with type 1 diabetes presents with vomiting, abdominal pain, lethargy, and drowsiness. His blood glucose is 350 mg/dL, and ABG shows the following \u2013 pH 7.24, S. Na 130 mEq/L, S. K 3.0 mEq/L, S. HCO3- 14 mEq/L, and S. Cl 88 mEq/L. His BP is 90/60 mm Hg, and IV fluids were rushed. Which of the following is the most appropriate next step in management?",
      "options": [
        {
          "label": "A",
          "text": "IV Aspart",
          "correct": false
        },
        {
          "label": "B",
          "text": "IV KCl",
          "correct": true
        },
        {
          "label": "C",
          "text": "IV NaHCO3",
          "correct": false
        },
        {
          "label": "D",
          "text": "CT head",
          "correct": false
        }
      ],
      "correct_answer": "B. IV KCl",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) IV KCl</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 Option A. IV Aspart: Insulin therapy is essential in DKA but should be started after correcting hypokalemia. Regular insulin is preferred for IV use in view of lesser cost but rapid acting analogs can also be used for IV use and are not contraindicated.</li><li>\u2022 Option A. IV Aspart:</li><li>\u2022 Option C. IV NaHCO3: Sodium bicarbonate is generally not recommended in DKA unless the pH is less than 6.9 or there are significant cardiac complications.</li><li>\u2022 Option C. IV NaHCO3:</li><li>\u2022 Option D. CT head: Cerebral edema is a rare complication of DKA and usually occurs in children during treatment. It is not the immediate priority in this scenario.</li><li>\u2022 Option D. CT head:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 :</li><li>\u27a4 Administer IV potassium chloride to correct hypokalemia before initiating insulin therapy in DKA to prevent severe hypokalemia.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "b5e71947",
      "audio": ""
    },
    {
      "text": "A 45-year-old man presents with recurrent hypoglycemia, confirmed by Whipple's triad. Laboratory investigations reveal a beta-hydroxybutyrate (\u03b2-OHB) level of 5 mmol/L and a poor blood glucose response to glucagon. The most likely diagnosis is:",
      "options": [
        {
          "label": "A",
          "text": "Insulinoma",
          "correct": false
        },
        {
          "label": "B",
          "text": "Factitious hypoglycemia due to sulfonylurea",
          "correct": false
        },
        {
          "label": "C",
          "text": "Non-insulin-mediated hypoglycemia",
          "correct": true
        },
        {
          "label": "D",
          "text": "IGF-2 related hypoglycemia",
          "correct": false
        }
      ],
      "correct_answer": "C. Non-insulin-mediated hypoglycemia",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Non-insulin-mediated hypoglycemia</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 Option A. Insulinoma: This would typically present with suppressed ketone levels due to the inhibitory effect of excess insulin on lipolysis and ketogenesis.</li><li>\u2022 Option A. Insulinoma:</li><li>\u2022 Option B. Factitious hypoglycemia due to sulfonylurea: Sulfonylureas increase insulin secretion, and hypoglycemia due to these medications would and tend to have suppressed \u03b2-OHB (< 2.7 mmol/L) in view of hyperinsulinemia.</li><li>\u2022 Option B. Factitious hypoglycemia due to sulfonylurea:</li><li>\u2022 Option D. IGF-2 related hypoglycemia: This is a rare cause of hypoglycemia and tend to have suppressed \u03b2-OHB (< 2.7 mmol/L) in view of insulin like action.</li><li>\u2022 Option D. IGF-2 related hypoglycemia:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Elevated \u03b2-OHB levels and poor response to glucagon indicate non-insulin-mediated hypoglycemia, such as critical illness or organ failure.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "bfc59a3b",
      "audio": ""
    },
    {
      "text": "A 40-year-old patient presents with dizziness. On examination, his BP is 180/110 mm Hg, and he has stretch marks in the trunk. His blood reports show a serum potassium (S. Potassium) of 2.7 mEq/L and HCO3- of 31 mEq/L. He also has elevated aldosterone levels, and after a dexamethasone suppression test, his serum cortisol was 60 nmol/L. What is the likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Cushing's syndrome",
          "correct": false
        },
        {
          "label": "B",
          "text": "Conn's syndrome",
          "correct": false
        },
        {
          "label": "C",
          "text": "Liddle's syndrome",
          "correct": false
        },
        {
          "label": "D",
          "text": "Connshing syndrome",
          "correct": true
        }
      ],
      "correct_answer": "D. Connshing syndrome",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Connshing syndrome</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Cushing's syndrome: Even though patient has features of Cushing\u2019s syndrome, he also has elevated aldosterone, hence it is not the accurate diagnosis.</li><li>\u2022 Option A. Cushing's syndrome:</li><li>\u2022 Option B. Conn\u2019s syndrome : Even though patient has features of Conn\u2019s syndrome, he also has elevated cortisol, hence it is not the accurate diagnosis.</li><li>\u2022 Option B.</li><li>\u2022 Conn\u2019s syndrome</li><li>\u2022 Option C. Liddle's syndrome: This is a rare genetic disorder causing similar electrolyte abnormalities but with normal or low aldosterone levels.</li><li>\u2022 Option C. Liddle's syndrome:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The combination of features indicating both Conn's syndrome (mineralocorticoid excess with hypertension, hypokalemia, and metabolic alkalosis) and Cushing's syndrome (elevated cortisol levels after dexamethasone suppression) points towards Connshing syndrome, where both aldosterone and cortisol are elevated.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "7b0a3bac",
      "audio": ""
    },
    {
      "text": "A 36-year-old man presents to the clinic reporting ankle swelling. On examination, his blood pressure is elevated at 162/86, and he has bilateral ankle edema. Laboratory studies show a potassium of 2.9 and normal creatinine. Which of the following studies is recommended next?",
      "options": [
        {
          "label": "A",
          "text": "Dexamethasone suppression",
          "correct": false
        },
        {
          "label": "B",
          "text": "CT of adrenals",
          "correct": false
        },
        {
          "label": "C",
          "text": "Plasma renin and aldosterone",
          "correct": true
        },
        {
          "label": "D",
          "text": "Urine metanephrines",
          "correct": false
        }
      ],
      "correct_answer": "C. Plasma renin and aldosterone",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Plasma renin and aldosterone</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Dexamethasone suppression: This test is used to diagnose Cushing's syndrome (excess cortisol production). While Cushing's syndrome can cause hypertension, it is not typically associated with hypokalemia and edema.</li><li>\u2022 Option A. Dexamethasone suppression:</li><li>\u2022 Option B. CT of adrenals: This imaging study can be useful to identify adrenal tumors, but it should be performed after biochemical confirmation of hyperaldosteronism.</li><li>\u2022 Option B. CT of adrenals:</li><li>\u2022 Option D. Urine metanephrines: This test is used to diagnose pheochromocytoma, a tumor that produces catecholamines. While pheochromocytoma can cause hypertension, it is not typically associated with hypokalemia and edema.</li><li>\u2022 Option D. Urine metanephrines:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The patient's presentation (hypertension, hypokalemia, and edema) suggests hyperaldosteronism. The initial test should be measuring plasma renin and aldosterone levels to confirm the diagnosis and determine if the cause is primary (adrenal) or secondary.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "2be72923",
      "audio": ""
    },
    {
      "text": "A 34-year-old man presents with resistant hypertension and a serum potassium level of 2.9 mEq/L, with normal creatinine. Which of the antihypertensives need not be stopped prior to the test you are about to perform to screen for the disease?",
      "options": [
        {
          "label": "A",
          "text": "Prazosin",
          "correct": true
        },
        {
          "label": "B",
          "text": "Propranolol",
          "correct": false
        },
        {
          "label": "C",
          "text": "Spironolactone",
          "correct": false
        },
        {
          "label": "D",
          "text": "Enalapril",
          "correct": false
        }
      ],
      "correct_answer": "A. Prazosin",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/14/screenshot-2024-08-14-165846.png"
      ],
      "explanation": "<p><strong>Ans. A) Prazosin</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Propranolol (beta-blocker): Can lower plasma renin activity (PRA), potentially masking primary aldosteronism (false positive test). It should be stopped 2 weeks before the test.</li><li>\u2022 Option B. Propranolol (beta-blocker):</li><li>\u2022 Option C. Spironolactone (mineralocorticoid receptor antagonist): Directly affects aldosterone levels (false positive test). and should be stopped 4 weeks before the test.</li><li>\u2022 Option C. Spironolactone (mineralocorticoid receptor antagonist):</li><li>\u2022 Option D. Enalapril (ACE inhibitor): Can increase plasma renin activity, potentially leading to a false-negative result. It should be stopped 2 weeks before the test.</li><li>\u2022 Option D. Enalapril (ACE inhibitor):</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 Prazosin (an \u03b1-1 blocker) does not significantly affect the renin-angiotensin-aldosterone system (RAAS) and can be continued during testing for primary aldosteronism. Other medications like beta-blockers, mineralocorticoid receptor antagonists, and ACE inhibitors should be stopped prior to testing.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "5650356f",
      "audio": ""
    },
    {
      "text": "A 43-year-old man with episodic, severe hypertension is referred with mild depression and current medications including sertraline, atenolol, amlodipine, and enalapril. Urine 24-hour total metanephrines show a borderline (1.5x) elevation. What is the next most appropriate step?",
      "options": [
        {
          "label": "A",
          "text": "Hold atenolol for 1 week and repeat testing",
          "correct": true
        },
        {
          "label": "B",
          "text": "Hold sertraline for 1 week and repeat testing",
          "correct": false
        },
        {
          "label": "C",
          "text": "Start \u03b1-blockers and then \u03b2-blockers",
          "correct": false
        },
        {
          "label": "D",
          "text": "CT of the abdomen and pelvis",
          "correct": false
        }
      ],
      "correct_answer": "A. Hold atenolol for 1 week and repeat testing",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Hold atenolol for 1 week and repeat testing</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Hold sertraline for 1 week and repeat testing: Sertraline is a selective serotonin reuptake inhibitor, not a TCA. Hence its unlikely to affect the test.</li><li>\u2022 Option B. Hold sertraline for 1 week and repeat testing:</li><li>\u2022 Option C. Start \u03b1-blockers and then \u03b2-blockers: This may be the initial management of pheochromocytoma, once the diagnosis is established, but NOT appropriate in this case with borderline metanephrine elevations.</li><li>\u2022 Option C. Start \u03b1-blockers and then \u03b2-blockers:</li><li>\u2022 Option D. CT of the abdomen and pelvis: This may be done to localize pheochromocytoma, once biochemical diagnosis is established.</li><li>\u2022 Option D. CT of the abdomen and pelvis:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 :</li><li>\u27a4 Borderline elevated metanephrines can be influenced by certain medications, including beta-blockers like atenolol. The next step is to stop potentially interfering medications and repeat the test to confirm the diagnosis.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "5f3c7c81",
      "audio": ""
    },
    {
      "text": "Which of the following is the most common mutation found in ACTH-secreting pituitary adenomas?",
      "options": [
        {
          "label": "A",
          "text": "PRKAR1A",
          "correct": false
        },
        {
          "label": "B",
          "text": "USP8",
          "correct": true
        },
        {
          "label": "C",
          "text": "GNAS1",
          "correct": false
        },
        {
          "label": "D",
          "text": "PRKACA",
          "correct": false
        }
      ],
      "correct_answer": "B. USP8",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) USP8</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. PRKAR1A: Mutations in this gene are associated with Carney complex, which is usually associated with PPNAD (Primary pigmented Nodular Adrenal Disease).</li><li>\u2022 Option A. PRKAR1A:</li><li>\u2022 Option C. GNAS1: Activating mutations in this gene can result in McCune-Albright syndrome (MAS). Cushing\u2019s syndrome in MAS is usually ACTH independent.</li><li>\u2022 Option C. GNAS1:</li><li>\u2022 Option D. PRKACA: Mutations in this gene are found in a subset (40%) of cortisol-producing adrenal adenomas and are not typically associated with ACTH-secreting pituitary adenomas.</li><li>\u2022 Option D. PRKACA:</li><li>\u2022 Another mutation in a tumor suppressor gene ARMC5 have been identified as a prevalent cause of Cushing\u2019s due to bilateral macronodular adrenal hyperplasia.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 USP8 mutations are the most frequent genetic alterations found in ACTH-secreting pituitary adenomas, leading to increased deubiquitination and stabilization of the EGFR, which promotes ACTH synthesis and secretion.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "5bfeb442",
      "audio": ""
    },
    {
      "text": "Which of the following is the gold standard to differentiate Cushing's disease (ACTH-producing pituitary adenoma) from ectopic Cushing's syndrome?",
      "options": [
        {
          "label": "A",
          "text": "Inferior petrosal sinus sampling.",
          "correct": true
        },
        {
          "label": "B",
          "text": "High dose Dexamethasone suppression test.",
          "correct": false
        },
        {
          "label": "C",
          "text": "CRH stimulation test.",
          "correct": false
        },
        {
          "label": "D",
          "text": "MRI of the pituitary.",
          "correct": false
        }
      ],
      "correct_answer": "A. Inferior petrosal sinus sampling.",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Inferior petrosal sinus sampling.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. High dose Dexamethasone suppression test: While this test can help distinguish between different causes of Cushing's syndrome, it is not as specific as IPSS in differentiating pituitary from ectopic ACTH secretion.</li><li>\u2022 Option B. High dose Dexamethasone suppression test:</li><li>\u2022 Cortisol suppression >50% after q6h 2 mg DEX for 2 days is suggestive of Cushing\u2019s disease.</li><li>\u2022 Cortisol suppression >50% after q6h 2 mg DEX for 2 days is suggestive of Cushing\u2019s disease.</li><li>\u2022 Option C. CRH stimulation test: This test can be helpful in the evaluation of Cushing's syndrome, but it is not the gold standard for differentiating between pituitary and ectopic sources of ACTH.</li><li>\u2022 Option C. CRH stimulation test:</li><li>\u2022 ACTH increase >40% at 15\u201330 min + cortisol increase >20% at 45\u201360 min after CRH 100 \u03bcg IV is suggestive of Cushing\u2019s disease.</li><li>\u2022 ACTH increase >40% at 15\u201330 min + cortisol increase >20% at 45\u201360 min after CRH 100 \u03bcg IV is suggestive of Cushing\u2019s disease.</li><li>\u2022 Option D. MRI of the pituitary: MRI can detect pituitary tumors, but not all ACTH-producing tumors are visible on MRI. Additionally, incidental pituitary lesions can be found in patients without Cushing's disease.</li><li>\u2022 Option D. MRI of the pituitary:</li><li>\u2022 In the presence of cortisol & ACTH excess, a lesion > 6 mm is suggestive of Cushing\u2019s disease.</li><li>\u2022 In the presence of cortisol & ACTH excess, a lesion > 6 mm is suggestive of Cushing\u2019s disease.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Inferior petrosal sinus sampling (IPSS) is the gold standard for differentiating Cushing's disease from ectopic ACTH syndrome by measuring ACTH levels from the inferior petrosal sinuses and comparing them with peripheral levels after CRH administration.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "2c5e476f",
      "audio": ""
    },
    {
      "text": "A 38-year-old woman with resistant hypertension and muscle weakness has a serum potassium of 2.8 mEq/L. Her plasma renin activity (PRA) is very low and her aldosterone levels are elevated. What is the most common cause?",
      "options": [
        {
          "label": "A",
          "text": "Bilateral adrenal hyperplasia",
          "correct": true
        },
        {
          "label": "B",
          "text": "Unilateral adrenal adenoma",
          "correct": false
        },
        {
          "label": "C",
          "text": "Adrenocortical carcinoma",
          "correct": false
        },
        {
          "label": "D",
          "text": "Pheochromocytoma",
          "correct": false
        }
      ],
      "correct_answer": "A. Bilateral adrenal hyperplasia",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Bilateral adrenal hyperplasia</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Unilateral adrenal adenoma: While a common cause of primary aldosteronism, it is less frequent than bilateral adrenal hyperplasia.</li><li>\u2022 Option B. Unilateral adrenal adenoma:</li><li>\u2022 Option C. Adrenocortical carcinoma: This is a rare cause of primary aldosteronism.</li><li>\u2022 Option C. Adrenocortical carcinoma:</li><li>\u2022 Option D. Pheochromocytoma: This is a tumor of the adrenal medulla that secretes catecholamines. It is not associated with the typical findings of primary aldosteronism.</li><li>\u2022 Option D. Pheochromocytoma:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 Bilateral adrenal hyperplasia is the most common cause of primary aldosteronism, accounting for 60-70% of cases. It leads to elevated aldosterone and low plasma renin activity, causing hypertension and hypokalemia.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "7f28f309",
      "audio": ""
    },
    {
      "text": "A 24-year-old man presents with severe hypertension, hypokalemia, and metabolic alkalosis. His brother died of intracranial hemorrhage (ICH) at the age of 12. His plasma renin and aldosterone levels are low, and his blood pressure normalized after adding spironolactone. Which of the following is the most likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Liddle syndrome",
          "correct": false
        },
        {
          "label": "B",
          "text": "Gordon syndrome (PHA2)",
          "correct": false
        },
        {
          "label": "C",
          "text": "Gitelman syndrome",
          "correct": false
        },
        {
          "label": "D",
          "text": "Apparent mineralocorticoid excess (SAME)",
          "correct": true
        }
      ],
      "correct_answer": "D. Apparent mineralocorticoid excess (SAME)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Apparent mineralocorticoid excess (SAME)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Liddle syndrome: Response to spironolactone would be poor. Patients typically respond to amiloride (as this disorder is due to hyperfunctioning ENaC channels in the principal cells).</li><li>\u2022 Option A. Liddle syndrome:</li><li>\u2022 Option B. Gordon syndrome (PHA2): Response to spironolactone would be poor and patients usually present with hypertension, hyperkalemia and metabolic acidosis. Patients typically respond to thiazides (as this disorder is due to hyperfunctioning Na-Cl transporters in the DCT).</li><li>\u2022 Option B. Gordon syndrome (PHA2):</li><li>\u2022 Option C. Gitelman syndrome: This syndrome can cause hypokalemia and metabolic alkalosis, but patients tend to be normotensive and renin/aldosterone levels would be elevated.</li><li>\u2022 Option C. Gitelman syndrome:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 SAME is caused by a deficiency of 11\u03b2-hydroxysteroid dehydrogenase type 2, leading to cortisol acting as a potent mineralocorticoid. The patient's response to spironolactone supports this diagnosis.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "c8c0c66f",
      "audio": ""
    },
    {
      "text": "A 40-year-old man presents with resistant hypertension> His serum potassium is 3 mEq/L, and his serum HCO3- is 29 mEq/L. His renin levels were low and aldosterone levels were elevated. What is the confirmatory test for the suspected diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Dexamethasone suppression test",
          "correct": false
        },
        {
          "label": "B",
          "text": "Saline infusion test",
          "correct": true
        },
        {
          "label": "C",
          "text": "CT scan of the abdomen",
          "correct": false
        },
        {
          "label": "D",
          "text": "Urinary metanephrines",
          "correct": false
        }
      ],
      "correct_answer": "B. Saline infusion test",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Saline infusion test</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Dexamethasone suppression test: This test is used to diagnose Cushing's syndrome (excess cortisol production), not primary aldosteronism.</li><li>\u2022 Option A. Dexamethasone suppression test:</li><li>\u2022 Option C. CT scan of the abdomen: This imaging test can help visualize adrenal glands and identify tumors, but it does not confirm the functional diagnosis of primary aldosteronism.</li><li>\u2022 Option C. CT scan of the abdomen:</li><li>\u2022 Option D. Urinary metanephrines: This test is used to diagnose pheochromocytoma, which is not consistent with the patient's presentation.</li><li>\u2022 Option D. Urinary metanephrines:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The saline infusion test is the confirmatory test for primary aldosteronism. It involves administering saline and measuring aldosterone levels, which should suppress if primary aldosteronism is present.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "f914f7bf",
      "audio": ""
    },
    {
      "text": "A 54-year-old man presents with an incidental 6 cm adrenal lesion with a radiodensity of 45 HU. Which of the following is NOT predictive of adrenocortical cancer (ACC)?",
      "options": [
        {
          "label": "A",
          "text": "Radiodensity > 20 HU",
          "correct": false
        },
        {
          "label": "B",
          "text": "Size \u2265 4cm",
          "correct": false
        },
        {
          "label": "C",
          "text": "Elevated steroid precursors in urine",
          "correct": false
        },
        {
          "label": "D",
          "text": "Calcifications in the adrenal gland",
          "correct": true
        }
      ],
      "correct_answer": "D. Calcifications in the adrenal gland",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Calcifications in adrenal gland</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Radiodensity > 20 HU: Adrenocortical carcinomas typically have higher radiodensity on unenhanced CT scans (>20 HU) due to their lower fat content.</li><li>\u2022 Option A. Radiodensity > 20 HU:</li><li>\u2022 Option B. Size \u2265 4 cm: Larger adrenal lesions are more likely to be malignant. A 6 cm lesion is highly suspicious for ACC.</li><li>\u2022 Option B. Size \u2265 4 cm:</li><li>\u2022 Option C. Elevated steroid precursors in urine: Adrenocortical carcinomas often produce excess steroid precursors, which can be detected in urine. This is a suggestive feature of malignancy.</li><li>\u2022 Option C. Elevated steroid precursors in urine:</li><li>\u2022 A recently introduced diagnostic test, urine steroid metabolomics, has a 2x higher PPV than imaging in detecting ACC, based on a distinct \u201csteroid fingerprint\u201d with accumulating precursor steroids in 24-h urine.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Calcifications can be present in adrenal lesions but are more commonly associated with benign lesions like adrenal adenomas and do not necessarily predict malignancy.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "cf7c6071",
      "audio": ""
    },
    {
      "text": "A 20-year-old woman presents with abdominal pain, fever and vomiting. She takes insulin for type 1 diabetes. On examination, her mucosa is dry and the appearance is shown in the image. You order an ABG and the results are as follows - pH \u2013 7.29, Na \u2013 129 mEq/L, K \u2013 5.6 mEq/L, HCO3- 18 mEq/L, Cl \u2013 101 mEq/L and her RBS is 89 mg/dL. Her ECG shows sinus tachycardia. Her BP is 80/40 mm Hg and her PR is 122/min. You give an IV fluid bolus and her BP slightly improves. What is the most important treatment?",
      "options": [
        {
          "label": "A",
          "text": "Give hydrocortisone 100mg IV.",
          "correct": true
        },
        {
          "label": "B",
          "text": "Start IV insulin infusion.",
          "correct": false
        },
        {
          "label": "C",
          "text": "Start IV NaHCO3.",
          "correct": false
        },
        {
          "label": "D",
          "text": "Start IV Insulin + Dextrose.",
          "correct": false
        }
      ],
      "correct_answer": "A. Give hydrocortisone 100mg IV.",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/14/screenshot-2024-08-14-173002.png"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Give hydrocortisone 100mg IV.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Start IV insulin infusion: While the patient has type 1 diabetes, her current blood glucose is within the normal range, and insulin infusion is not the priority in this emergency situation.</li><li>\u2022 Option B. Start IV insulin infusion:</li><li>\u2022 Option C. Start IV NaHCO3: Correcting acidosis is important, but the primary concern is addressing the underlying adrenal insufficiency with hydrocortisone.</li><li>\u2022 Option C. Start IV NaHCO3:</li><li>\u2022 Option D. Start IV Insulin + Dextrose: This is an initial therapy in hyperkalemia, to transiently lower serum potassium levels. But in adrenal crisis, correction of underlying cause is important by administering hydrocortisone.</li><li>\u2022 Option D. Start IV Insulin + Dextrose:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 The patient's presentation is strongly suggestive of an adrenal crisis. Administering intravenous hydrocortisone is the most important treatment to replace the deficient cortisol.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "c27bbfa1",
      "audio": ""
    },
    {
      "text": "A 16-year-old boy with known Congenital Adrenal Hyperplasia (CAH) presents with bilateral testicular masses. His serum ACTH levels are elevated, and ultrasound reveals B/L hypoechoic lesions in the testes. Which of the following is the most appropriate next step?",
      "options": [
        {
          "label": "A",
          "text": "Immediate surgical removal of the testicular masses",
          "correct": false
        },
        {
          "label": "B",
          "text": "Start high-dose glucocorticoid therapy",
          "correct": true
        },
        {
          "label": "C",
          "text": "Initiate testosterone replacement therapy",
          "correct": false
        },
        {
          "label": "D",
          "text": "Perform a biopsy of the testicular masses to rule out malignancy",
          "correct": false
        }
      ],
      "correct_answer": "B. Start high-dose glucocorticoid therapy",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Start high-dose glucocorticoid therapy</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Immediate surgical removal of the testicular masses: Surgery is not the initial approach for adrenal rest tumors. Medical management with glucocorticoids is usually attempted first.</li><li>\u2022 Option A. Immediate surgical removal of the testicular masses:</li><li>\u2022 Option C. Initiate testosterone replacement therapy: Testosterone replacement is not indicated for adrenal rest tumors and may even worsen the condition by stimulating further tumor growth.</li><li>\u2022 Option C. Initiate testosterone replacement therapy:</li><li>\u2022 Option D. Perform a biopsy of the testicular masses to rule out malignancy: While biopsy can be considered in cases with atypical features or lack of response to glucocorticoids, it is not the most appropriate initial step. Adrenal rest tumors are typically benign, and the clinical presentation and imaging findings strongly suggest this diagnosis.</li><li>\u2022 Option D. Perform a biopsy of the testicular masses to rule out malignancy:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Bilateral testicular masses in a patient with congenital adrenal hyperplasia (CAH) are likely due to testicular adrenal rest tumors (TART). High-dose glucocorticoid therapy suppresses ACTH production and induces regression of the tumors.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "14a194ff",
      "audio": ""
    },
    {
      "text": "Screening for Parathyroid disorder in MEN 1 should begin at the age of?",
      "options": [
        {
          "label": "A",
          "text": "5 years",
          "correct": false
        },
        {
          "label": "B",
          "text": "8 years",
          "correct": true
        },
        {
          "label": "C",
          "text": "20 years",
          "correct": false
        },
        {
          "label": "D",
          "text": "15 years",
          "correct": false
        }
      ],
      "correct_answer": "B. 8 years",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/14/screenshot-2024-08-14-175419.png"
      ],
      "explanation": "<p><strong>Ans. B) 8 years</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. 5 years: This is when screening for anterior pituitary tumours & insulinomas begin in MEN1.</li><li>\u2022 Option A. 5 years:</li><li>\u2022 Option C. 20 years: This is when screening for gastrinomas begin in MEN 1.</li><li>\u2022 Option C. 20 years:</li><li>\u2022 Option D. 15 years: This is when screening for carcinoids (thymic/bronchial) begin in MEN 1.</li><li>\u2022 Option D. 15 years:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Screening for primary hyperparathyroidism in MEN1 should begin at 8 years of age.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "65149473",
      "audio": ""
    },
    {
      "text": "Which of the following is NOT a feature of MEN2B?",
      "options": [
        {
          "label": "A",
          "text": "Medullated corneal nerve fibers",
          "correct": false
        },
        {
          "label": "B",
          "text": "Intestinal dysfunction",
          "correct": false
        },
        {
          "label": "C",
          "text": "Mutation in cysteine-rich domain of RET",
          "correct": true
        },
        {
          "label": "D",
          "text": "Most common mutation is RET codon 918",
          "correct": false
        }
      ],
      "correct_answer": "C. Mutation in cysteine-rich domain of RET",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Mutation in cysteine-rich domain of RET</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Medullated corneal nerve fibers: This is a distinctive feature of MEN2B.</li><li>\u2022 Option A. Medullated corneal nerve fibers:</li><li>\u2022 Option B. Intestinal dysfunction: This is a common feature due to intestinal ganglioneuromatosis.</li><li>\u2022 Option B. Intestinal dysfunction:</li><li>\u2022 Option D. Most common mutation is RET codon 918: This is the characteristic mutation in MEN2B (seen in 95% cases).</li><li>\u2022 Option D. Most common mutation is RET codon 918:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 MEN2B is characterized by mutations in the tyrosine kinase domain of RET, not the cysteine-rich domain.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "30e1c035",
      "audio": ""
    },
    {
      "text": "A couple comes for counseling regarding their newborn's health. The father of the child had an MTC, was operated on recently, and was known to have a RET codon 918 mutation. The newborn has been screened and carries the same mutation as well. What will be your advice regarding the newborn?",
      "options": [
        {
          "label": "A",
          "text": "S. Calcium at 11 years",
          "correct": false
        },
        {
          "label": "B",
          "text": "Immediate total thyroidectomy",
          "correct": true
        },
        {
          "label": "C",
          "text": "Plasma metanephrines at 16 years",
          "correct": false
        },
        {
          "label": "D",
          "text": "MRI pituitary at 5 years",
          "correct": false
        }
      ],
      "correct_answer": "B. Immediate total thyroidectomy",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/14/screenshot-2024-08-14-180531.png"
      ],
      "explanation": "<p><strong>Ans. B) Immediate total thyroidectomy</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. S. Calcium at 11 years: Recommended for RET codon 634 or 883 mutations, where hyperparathyroidism is common. Hyperparathyroidism is not a feature of codon 918 mutations, hence screening is NOT recommended. For mutations other than For 663, 883 and 918 \u2013 screening can be started at 16 years.</li><li>\u2022 Option A. S. Calcium at 11 years:</li><li>\u2022 Option C. Plasma metanephrines at 16 years: Recommended for screening of pheochromocytoma for RET codon mutations (other than 663, 883 and 918). For 663, 883 and 918 mutations \u2013 screening should be started at 11 years.</li><li>\u2022 Option C. Plasma metanephrines at 16 years:</li><li>\u2022 Option D. MRI pituitary at 5 years: This is the recommendations for screening pituitary tumors in case of MEN1. Pituitary tumors are not associated with MEN2B.</li><li>\u2022 Option D. MRI pituitary at 5 years:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Immediate total thyroidectomy is recommended for newborns with RET codon 918 mutation to prevent medullary thyroid carcinoma (MTC).</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "f8b702e2",
      "audio": ""
    },
    {
      "text": "Which of the following is the most common endocrine manifestation of Carney complex?",
      "options": [
        {
          "label": "A",
          "text": "Cushing's syndrome",
          "correct": true
        },
        {
          "label": "B",
          "text": "Addison's disease",
          "correct": false
        },
        {
          "label": "C",
          "text": "Hyperparathyroidism",
          "correct": false
        },
        {
          "label": "D",
          "text": "Hypothyroidism",
          "correct": false
        }
      ],
      "correct_answer": "A. Cushing's syndrome",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Cushing's syndrome</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Addison's disease: This is primary adrenal insufficiency, which is not a typical feature of Carney complex.</li><li>\u2022 Option B. Addison's disease:</li><li>\u2022 Option C. Hyperparathyroidism: While parathyroid adenomas can occur in CNC, they are less common than PPNAD.</li><li>\u2022 Option C. Hyperparathyroidism:</li><li>\u2022 Option D. Hypothyroidism: Thyroid involvement in CNC is typically in the form of thyroid nodules or cancer, not hypothyroidism.</li><li>\u2022 Option D. Hypothyroidism:</li><li>\u2022 Summary: Carney Complex \u2013</li><li>\u2022 Summary:</li><li>\u2022 Features: Spotty skin pigmentation, myxomas , psammomatous melanotic schwannomas , endocrine tumors (adrenal, Sertoli cells, somatotropes, thyroid, ovary). Most common endocrine manifestation: Cushing's syndrome due to primary pigmented nodular adrenal disease (PPNAD).</li><li>\u2022 Features: Spotty skin pigmentation, myxomas , psammomatous melanotic schwannomas , endocrine tumors (adrenal, Sertoli cells, somatotropes, thyroid, ovary).</li><li>\u2022 Features:</li><li>\u2022 Most common endocrine manifestation: Cushing's syndrome due to primary pigmented nodular adrenal disease (PPNAD).</li><li>\u2022 Most common endocrine manifestation:</li><li>\u2022 Atypical Cushing's presentation: Patients are often thin, have short stature, muscle/skin wasting, and osteoporosis. Periodic Cushing's syndrome: Fluctuating cortisol levels over days or weeks. Can have paradoxical elevation of cortisol after dexamethasone administration.</li><li>\u2022 Atypical Cushing's presentation: Patients are often thin, have short stature, muscle/skin wasting, and osteoporosis.</li><li>\u2022 Periodic Cushing's syndrome: Fluctuating cortisol levels over days or weeks.</li><li>\u2022 Can have paradoxical elevation of cortisol after dexamethasone administration.</li><li>\u2022 Other endocrine manifestations: Acromegaly, testicular tumors (Sertoli cell, Leydig cell), thyroid tumors, ovarian cysts, breast duct adenomas. Genetics:</li><li>\u2022 Other endocrine manifestations: Acromegaly, testicular tumors (Sertoli cell, Leydig cell), thyroid tumors, ovarian cysts, breast duct adenomas.</li><li>\u2022 Other endocrine manifestations:</li><li>\u2022 Genetics:</li><li>\u2022 CNC1: Mutations in PRKAR1A gene (tumor suppressor) on chromosome 17q24.2. CNC2: Gene on chromosome 2p16 (not yet identified).</li><li>\u2022 CNC1: Mutations in PRKAR1A gene (tumor suppressor) on chromosome 17q24.2.</li><li>\u2022 CNC2: Gene on chromosome 2p16 (not yet identified).</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The most common endocrine manifestation of Carney complex is Cushing's syndrome due to primary pigmented nodular adrenocortical disease (PPNAD).</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "a81caafa",
      "audio": ""
    },
    {
      "text": "Which of the following is the first manifestation of APS 1?",
      "options": [
        {
          "label": "A",
          "text": "Type 1 DM",
          "correct": false
        },
        {
          "label": "B",
          "text": "Mucocutaneous candidiasis",
          "correct": true
        },
        {
          "label": "C",
          "text": "Hypoparathyroidism",
          "correct": false
        },
        {
          "label": "D",
          "text": "Adrenal insufficiency",
          "correct": false
        }
      ],
      "correct_answer": "B. Mucocutaneous candidiasis",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Mucocutaneous candidiasis</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Type 1 DM: It is uncommon in APS-1 but a common feature of APS-2.</li><li>\u2022 Option A. Type 1 DM:</li><li>\u2022 Option C. Hypoparathyroidism: Hypoparathyroidism typically develops after mucocutaneous candidiasis in APS-1.</li><li>\u2022 Option C. Hypoparathyroidism:</li><li>\u2022 Option D. Adrenal insufficiency: Adrenal insufficiency is usually the last component of the classic triad to appear.</li><li>\u2022 Option D. Adrenal insufficiency:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The first manifestation of APS-1 is typically mucocutaneous candidiasis, appearing in infancy or early childhood.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "5003f853",
      "audio": ""
    },
    {
      "text": "What is the karyotype most commonly associated with mixed gonadal dysgenesis (MGD)?",
      "options": [
        {
          "label": "A",
          "text": "45X/46XY",
          "correct": true
        },
        {
          "label": "B",
          "text": "45X/46XX",
          "correct": false
        },
        {
          "label": "C",
          "text": "45XY/45XXY",
          "correct": false
        },
        {
          "label": "D",
          "text": "46XX/46XY",
          "correct": false
        }
      ],
      "correct_answer": "A. 45X/46XY",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) 45X/46XY</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. 45X/46XX: This karyotype is associated with Turner mosaics.</li><li>\u2022 Option B. 45X/46XX:</li><li>\u2022 Option C. 45XY/45XXY: This karyotype combination is seen in Klinefelter mosaics.</li><li>\u2022 Option C. 45XY/45XXY:</li><li>\u2022 Option D. 46XX/46XY: This karyotype may be seen in Ovotesticular DSD (but most common is 46XX).</li><li>\u2022 Option D. 46XX/46XY:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The most common karyotype associated with mixed gonadal dysgenesis is 45,X/46,XY.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "7260b94e",
      "audio": ""
    },
    {
      "text": "A 17-year-old female presents with Tanner stage IV breast development but no menses. Ultrasound confirms a blind vaginal vault and no uterus or cervix. What lab test would be most helpful in finding the etiology of her problem?",
      "options": [
        {
          "label": "A",
          "text": "Pathologic examination of her gonads",
          "correct": false
        },
        {
          "label": "B",
          "text": "Serum thyroid-stimulating hormone level",
          "correct": false
        },
        {
          "label": "C",
          "text": "Serum prolactin level",
          "correct": false
        },
        {
          "label": "D",
          "text": "Karyotype",
          "correct": true
        }
      ],
      "correct_answer": "D. Karyotype",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Karyotype</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Pathologic examination of her gonads: While this can be informative, it is not the first-line test and may not be necessary if the karyotype confirms CAIS.</li><li>\u2022 Option A. Pathologic examination of her gonads:</li><li>\u2022 Option B. Serum thyroid-stimulating hormone level: Thyroid dysfunction is not a likely cause of this presentation.</li><li>\u2022 Option B. Serum thyroid-stimulating hormone level:</li><li>\u2022 Option C. Serum prolactin level: Hyperprolactinemia is not associated with the absence of uterus and cervix.</li><li>\u2022 Option C. Serum prolactin level:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 A karyotype is the most helpful test for differentiating between M\u00fcllerian agenesis and complete androgen insensitivity syndrome (CAIS).</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "2a79c00b",
      "audio": ""
    },
    {
      "text": "A 16-year-old girl presents with primary amenorrhea. On examination, she is tall and lacks secondary sexual characteristics. Which of the following is the most likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Kallman syndrome",
          "correct": false
        },
        {
          "label": "B",
          "text": "Turner syndrome",
          "correct": false
        },
        {
          "label": "C",
          "text": "Congenital adrenal hyperplasia (CAH) d",
          "correct": false
        },
        {
          "label": "D",
          "text": "Swyer syndrome",
          "correct": true
        }
      ],
      "correct_answer": "D. Swyer syndrome",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Swyer syndrome</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Kallman syndrome: Characterized by delayed or absent puberty and anosmia (loss of smell). Individuals with Kallman syndrome typically have a normal female karyotype (46,XX).</li><li>\u2022 Option A. Kallman syndrome:</li><li>\u2022 Option B. Turner syndrome: Characterized by short stature, webbed neck, and other features, with a karyotype of 45,X.</li><li>\u2022 Option B. Turner syndrome:</li><li>\u2022 Option C. Congenital adrenal hyperplasia (CAH): Typically presents with virilization (development of male sexual characteristics) in females due to excess androgen production. This is the opposite of what is seen in Swyer syndrome.</li><li>\u2022 Option C. Congenital adrenal hyperplasia (CAH):</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Swyer syndrome (46,XY gonadal dysgenesis) is characterized by a female phenotype with a male karyotype and lack of secondary sexual characteristics.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "39d480db",
      "audio": ""
    },
    {
      "text": "A newborn presents with ambiguous genitalia, clitoromegaly and partial fusion of the labio-scrotal folds. The newborn also shows hyperpigmentation and hypertension. Karyotype shows 46,XX. Which of the following laboratory findings would be most consistent with the diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Elevated 17-hydroxyprogesterone (17-OHP) levels",
          "correct": false
        },
        {
          "label": "B",
          "text": "Increased serum 11-deoxycorticosterone (11-DOC) levels",
          "correct": true
        },
        {
          "label": "C",
          "text": "Elevated DHEA-S (dehydroepiandrosterone sulfate) levels",
          "correct": false
        },
        {
          "label": "D",
          "text": "Decreased plasma renin activity",
          "correct": false
        }
      ],
      "correct_answer": "B. Increased serum 11-deoxycorticosterone (11-DOC) levels",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Increased serum 11-deoxycorticosterone (11-DOC) levels</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Elevated 17-OHP levels: This is primarily seen in 21-hydroxylase deficiency.</li><li>\u2022 Option A. Elevated 17-OHP levels:</li><li>\u2022 Option C. Elevated DHEA-S levels: While DHEA-S is elevated in CAH, it is not specific to 11\u03b2-hydroxylase deficiency and is also seen in 21-hydroxylase deficiency.</li><li>\u2022 Option C. Elevated DHEA-S levels:</li><li>\u2022 Option D. Decreased plasma renin activity: This is correct for 11\u03b2-hydroxylase deficiency, but it is not the most specific finding for this type of CAH.</li><li>\u2022 Option D. Decreased plasma renin activity:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Elevated serum 11-deoxycorticosterone (11-DOC) levels are indicative of 11\u03b2-hydroxylase deficiency in CAH.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "d21891dd",
      "audio": ""
    },
    {
      "text": "A 68-year-old male presents with congestive heart failure and sepsis. Thyroid function tests (TFT) reveal a low total T3, normal free T4 and normal TSH. What is the next step?",
      "options": [
        {
          "label": "A",
          "text": "Give Levothyroxine 200\u00b5g IV STAT",
          "correct": false
        },
        {
          "label": "B",
          "text": "Give Hydrocortisone 100mg IV STAT",
          "correct": false
        },
        {
          "label": "C",
          "text": "Give Levothyroxine 200\u00b5g and 100mg Hydrocortisone IV STAT",
          "correct": false
        },
        {
          "label": "D",
          "text": "Observation and repeat TFT after discharge",
          "correct": true
        }
      ],
      "correct_answer": "D. Observation and repeat TFT after discharge",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Observation and repeat TFT after discharge</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Give Levothyroxine 200\u00b5g IV STAT: Levothyroxine replacement is not indicated in SES and may even be harmful.</li><li>\u2022 Option A. Give Levothyroxine 200\u00b5g IV STAT:</li><li>\u2022 Option B. Give Hydrocortisone 100mg IV STAT: This could be appropriate for suspected adrenal insufficiency.</li><li>\u2022 Option B. Give Hydrocortisone 100mg IV STAT:</li><li>\u2022 Option C. Give Levothyroxine 200\u00b5g and 100mg Hydrocortisone IV STAT: This could be an appropriate treatment for myxedema coma.</li><li>\u2022 Option C. Give Levothyroxine 200\u00b5g and 100mg Hydrocortisone IV STAT:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 In patients with sick euthyroid syndrome, characterized by low total T3, normal free T4, and normal TSH in the context of critical illness, observation and repeat TFTs after recovery is the appropriate management.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "c0805791",
      "audio": ""
    },
    {
      "text": "A 40-year-old woman presents with a 2-week history of palpitations and excessive sweating. Physical examination reveals a non-tender thyroid gland. Thyroid function tests show an elevated free T4 and suppressed TSH. Radioactive iodine uptake (RAIU) scan is shown. Thyroglobulin levels are low. What is the likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Graves disease",
          "correct": false
        },
        {
          "label": "B",
          "text": "Thyrotoxicosis factitia",
          "correct": true
        },
        {
          "label": "C",
          "text": "Toxic Multinodular Goiter",
          "correct": false
        },
        {
          "label": "D",
          "text": "Thyroiditis",
          "correct": false
        }
      ],
      "correct_answer": "B. Thyrotoxicosis factitia",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/17/screenshot-2024-08-17-133042_3j62nY0.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Thyrotoxicosis factitia.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Graves' disease: Graves' disease is an autoimmune condition causing hyperthyroidism. It typically presents with a diffuse goiter, increased RAIU, and high thyroglobulin levels.</li><li>\u2022 Option A. Graves' disease:</li><li>\u2022 Option C. Toxic Multinodular Goiter: This condition also has an increased RAIU and increased thyroglobulin levels.</li><li>\u2022 Option C. Toxic Multinodular Goiter:</li><li>\u2022 Option D. Thyroiditis: RAIU can be suppressed but thyroglobulin levels are usually elevated in thyroiditis.</li><li>\u2022 Option D. Thyroiditis:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Thyrotoxicosis factitia is characterized by low radioactive iodine uptake (RAIU) and low thyroglobulin levels, indicating exogenous thyroid hormone use.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "de6b4750",
      "audio": ""
    },
    {
      "text": "Which of the following statements is false regarding congenital hypothyroidism?",
      "options": [
        {
          "label": "A",
          "text": "Thyroid dyshormonogenesis is the most common cause.",
          "correct": true
        },
        {
          "label": "B",
          "text": "Most infants appear normal at birth.",
          "correct": false
        },
        {
          "label": "C",
          "text": "The recommended initial dose of levothyroxine is 10-15 \u00b5g/kg/day.",
          "correct": false
        },
        {
          "label": "D",
          "text": "Early treatment can significantly improve neurodevelopmental outcomes.",
          "correct": false
        }
      ],
      "correct_answer": "A. Thyroid dyshormonogenesis is the most common cause.",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Thyroid dyshormonogenesis is the most common cause.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Most infants appear normal at birth: The majority of infants appear normal at birth (but classic features are prolonged jaundice, poor feeding, hypotonia, macroglossia, delayed bone maturation, and umbilical hernia).</li><li>\u2022 Option B. Most infants appear normal at birth:</li><li>\u2022 Option C. The recommended initial dose of levothyroxine is 10-15 \u00b5g/kg/day: When the diagnosis is confirmed, T4 is instituted at a dose of 10\u201315 \u03bcg/kg/day and the dose is adjusted by close monitoring of TSH levels.</li><li>\u2022 Option C. The recommended initial dose of levothyroxine is 10-15 \u00b5g/kg/day:</li><li>\u2022 Option D. Early treatment can significantly improve neurodevelopmental outcomes: Early treatment with T4 results in normal IQ levels, but subtle neurodevelopmental abnormalities may occur in those with the most severe hypothyroidism at diagnosis or when treatment is delayed or suboptimal.</li><li>\u2022 Option D. Early treatment can significantly improve neurodevelopmental outcomes:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Thyroid gland dysgenesis, not thyroid dyshormonogenesis, is the most common cause of congenital hypothyroidism.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "0178ed21",
      "audio": ""
    },
    {
      "text": "Match the following:",
      "options": [
        {
          "label": "A",
          "text": "A-iv, B-iii, C-ii, D-i",
          "correct": true
        },
        {
          "label": "B",
          "text": "A-iv, B-iii, C-i,D-ii",
          "correct": false
        },
        {
          "label": "C",
          "text": "A-iii, B-iv, C-i,D-ii",
          "correct": false
        },
        {
          "label": "D",
          "text": "A-iii, B-iv, C-ii,D-i",
          "correct": false
        }
      ],
      "correct_answer": "A. A-iv, B-iii, C-ii, D-i",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/17/whatsapp-image-2024-08-17-at-121458-pm.jpeg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) A-iv, B-iii, C-ii, D-i</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 If there is no residual thyroid function, the daily replacement dose of LT4 is usually 1.6 \u03bcg/kg body weight (typically 100\u2013150 \u03bcg/d) Adult patients under 60 years old without evidence of heart disease may be started on 50\u2013100 \u03bcg of LT4 daily. For adults with indications to treat in a subclinical hypothyroidism treatment is administered by starting with a low dose of LT4 (25\u201350 \u03bcg/d). In the elderly, especially patients with known coronary artery disease, the starting dose of LT4 is 12.5\u201325 \u03bcg/d.</li><li>\u2022 If there is no residual thyroid function, the daily replacement dose of LT4 is usually 1.6 \u03bcg/kg body weight (typically 100\u2013150 \u03bcg/d)</li><li>\u2022 Adult patients under 60 years old without evidence of heart disease may be started on 50\u2013100 \u03bcg of LT4 daily.</li><li>\u2022 For adults with indications to treat in a subclinical hypothyroidism treatment is administered by starting with a low dose of LT4 (25\u201350 \u03bcg/d).</li><li>\u2022 In the elderly, especially patients with known coronary artery disease, the starting dose of LT4 is 12.5\u201325 \u03bcg/d.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Standard Adult: 50-100 \u00b5g/day Post thyroidectomy: 100-150 \u00b5g/day Coronary Artery Disease: 12.5-25 \u00b5g/day Subclinical Hypothyroidism: 25-50 \u00b5g/day</li><li>\u27a4 Standard Adult: 50-100 \u00b5g/day</li><li>\u27a4 Post thyroidectomy: 100-150 \u00b5g/day</li><li>\u27a4 Coronary Artery Disease: 12.5-25 \u00b5g/day</li><li>\u27a4 Subclinical Hypothyroidism: 25-50 \u00b5g/day</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "27999353",
      "audio": ""
    },
    {
      "text": "A 35-year-old woman with a history of Graves' disease presents to the emergency department with fever, tachycardia, agitation, and vomiting. She recently underwent a dental procedure. Which of the following is the most appropriate initial treatment for her suspected condition?",
      "options": [
        {
          "label": "A",
          "text": "Propranolol",
          "correct": false
        },
        {
          "label": "B",
          "text": "Propylthiouracil (PTU)",
          "correct": true
        },
        {
          "label": "C",
          "text": "Radioactive iodine (RAI)",
          "correct": false
        },
        {
          "label": "D",
          "text": "Hydrocortisone",
          "correct": false
        }
      ],
      "correct_answer": "B. Propylthiouracil (PTU)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Propylthiouracil (PTU)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Propranolol (A): Can be used for cardio-protection but not immediately required.</li><li>\u2022 Option A. Propranolol (A):</li><li>\u2022 Option C. Radioactive iodine (C) : Not suitable for acute management of thyrotoxic crisis.</li><li>\u2022 Option C. Radioactive iodine (C)</li><li>\u2022 Option D. Hydrocortisone (D) : Adjunctive therapy in thyroid storm, can be added later.</li><li>\u2022 Option D. Hydrocortisone (D)</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Propylthiouracil (PTU) is the most appropriate initial treatment for thyrotoxic crisis (thyroid storm) due to its rapid onset of action and ability to inhibit peripheral conversion of T4 to T3.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "494b0bbf",
      "audio": ""
    },
    {
      "text": "A patient with thyrotoxicosis develops atrial fibrillation. Which of the following statements regarding their management is CORRECT?",
      "options": [
        {
          "label": "A",
          "text": "Age < 50 is a risk factor",
          "correct": false
        },
        {
          "label": "B",
          "text": "Long-term anticoagulation is unnecessary",
          "correct": true
        },
        {
          "label": "C",
          "text": "Digoxin sensitivity is increased",
          "correct": false
        },
        {
          "label": "D",
          "text": "Warfarin sensitivity is decreased",
          "correct": false
        }
      ],
      "correct_answer": "B. Long-term anticoagulation is unnecessary",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Long-term anticoagulation is unnecessary</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Age < 50 is a risk factor: Elderly patients (Age >50) are at increased risk.</li><li>\u2022 Option A. Age < 50 is a risk factor:</li><li>\u2022 Option C. Digoxin sensitivity is increased: Digoxin sensitivity is decreased because of increased renal clearance and increased number of Na-K ATPse.</li><li>\u2022 Option C. Digoxin sensitivity is increased:</li><li>\u2022 Option D. Warfarin sensitivity is decreased: Warfarin sensitivity is increased as production of vitamin K dependent clotting factors are reduced.</li><li>\u2022 Option D. Warfarin sensitivity is decreased:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Long-term anticoagulation is generally unnecessary in patients with atrial fibrillation and thyrotoxicosis, as spontaneous reversion to sinus rhythm often occurs with control of hyperthyroidism.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "7bebb190",
      "audio": ""
    },
    {
      "text": "Which of the following should be avoided in children with Graves disease?",
      "options": [
        {
          "label": "A",
          "text": "Propylthiouracil",
          "correct": true
        },
        {
          "label": "B",
          "text": "Methimazole",
          "correct": false
        },
        {
          "label": "C",
          "text": "Radioactive Iodine Ablation",
          "correct": false
        },
        {
          "label": "D",
          "text": "Thyroidectomy",
          "correct": false
        }
      ],
      "correct_answer": "A. Propylthiouracil",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Propylthiouracil</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Methimazole: Preferred treatment in children with Graves disease.</li><li>\u2022 Option B. Methimazole:</li><li>\u2022 Option C. Radioactive Iodine Ablation: Usually reserved for refractory/severe Graves disease in children.</li><li>\u2022 Option C. Radioactive Iodine Ablation:</li><li>\u2022 Option D. Thyroidectomy: Usually reserved for refractory/severe Graves disease in children.</li><li>\u2022 Option D. Thyroidectomy:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Propylthiouracil should be avoided in children with Graves' disease due to the risk of hepatitis.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "506a0273",
      "audio": ""
    },
    {
      "text": "A 25-year-old woman with Graves' disease undergoes RAI therapy. Two months later, she complains of persistent palpitations and heat intolerance. Which of the following is the most likely explanation for her persistent symptoms?",
      "options": [
        {
          "label": "A",
          "text": "RAI therapy is ineffective in young patients.",
          "correct": false
        },
        {
          "label": "B",
          "text": "The patient is experiencing a relapse of Graves' disease.",
          "correct": false
        },
        {
          "label": "C",
          "text": "The patient is developing hypothyroidism.",
          "correct": false
        },
        {
          "label": "D",
          "text": "The full effect of RAI therapy takes 2-3 months to manifest.",
          "correct": true
        }
      ],
      "correct_answer": "D. The full effect of RAI therapy takes 2-3 months to manifest.",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) The full effect of RAI therapy takes 2-3 months to manifest.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A . RAI therapy is ineffective in young patients: RAI is effective in all age groups.</li><li>\u2022 Option A</li><li>\u2022 RAI therapy is ineffective in young patients:</li><li>\u2022 Option B . The patient is experiencing a relapse of Graves' disease: Relapse is possible, but less likely within two months.</li><li>\u2022 Option B</li><li>\u2022 The patient is experiencing a relapse of Graves' disease:</li><li>\u2022 Option C . The patient is developing hypothyroidism: Hypothyroidism is a later complication of RAI.</li><li>\u2022 Option C</li><li>\u2022 The patient is developing hypothyroidism:</li><li>\u2022 Summary of RAIA in Graves:</li><li>\u2022 Summary of RAIA in Graves:</li><li>\u2022 Indication : Initial treatment or for relapses after antithyroid drugs. Tracer used: I131. Emits \u03b2 & \u03b3. t1/2 \u223c 8 days. Elderly/Cardiac Patients: Consider pretreatment with antithyroid drugs and beta-blockers (because of small, increased risk of Thyrotoxic Crisis) Carbimazole/Methimazole: Stop 2-3 days before and restart 3-7 days after RAI. PTU: Prolonged radioprotective effect, requires longer discontinuation or higher RAI dose. Persistence of Hyperthyroidism: Can persist for 2-3 months, managed with beta-blockers or antithyroid drugs. Safety Precautions: Avoid close contact with children and pregnant women for 5-7 days. Complications: Radiation Thyroiditis: Mild pain may occur 1-2 weeks after treatment. Flare of Orbitopathy: Especially in smokers. Consider prednisone pre-treatment. Permanent Hypothyroidism: Risk is 10-20% in the first year, 5% per year thereafter, requiring lifelong LT4 replacement. Possibly a small increased lifetime risk of solid cancers. Contraindications: Pregnancy, breastfeeding and suspected thyroid cancer.</li><li>\u2022 Indication : Initial treatment or for relapses after antithyroid drugs.</li><li>\u2022 Indication</li><li>\u2022 Tracer used: I131. Emits \u03b2 & \u03b3. t1/2 \u223c 8 days.</li><li>\u2022 Tracer used:</li><li>\u2022 Elderly/Cardiac Patients: Consider pretreatment with antithyroid drugs and beta-blockers (because of small, increased risk of Thyrotoxic Crisis) Carbimazole/Methimazole: Stop 2-3 days before and restart 3-7 days after RAI. PTU: Prolonged radioprotective effect, requires longer discontinuation or higher RAI dose.</li><li>\u2022 Elderly/Cardiac Patients:</li><li>\u2022 Carbimazole/Methimazole: Stop 2-3 days before and restart 3-7 days after RAI. PTU: Prolonged radioprotective effect, requires longer discontinuation or higher RAI dose.</li><li>\u2022 Carbimazole/Methimazole: Stop 2-3 days before and restart 3-7 days after RAI.</li><li>\u2022 PTU: Prolonged radioprotective effect, requires longer discontinuation or higher RAI dose.</li><li>\u2022 Persistence of Hyperthyroidism: Can persist for 2-3 months, managed with beta-blockers or antithyroid drugs.</li><li>\u2022 Persistence of Hyperthyroidism:</li><li>\u2022 Safety Precautions: Avoid close contact with children and pregnant women for 5-7 days.</li><li>\u2022 Safety Precautions:</li><li>\u2022 Complications: Radiation Thyroiditis: Mild pain may occur 1-2 weeks after treatment. Flare of Orbitopathy: Especially in smokers. Consider prednisone pre-treatment. Permanent Hypothyroidism: Risk is 10-20% in the first year, 5% per year thereafter, requiring lifelong LT4 replacement. Possibly a small increased lifetime risk of solid cancers.</li><li>\u2022 Complications:</li><li>\u2022 Radiation Thyroiditis: Mild pain may occur 1-2 weeks after treatment. Flare of Orbitopathy: Especially in smokers. Consider prednisone pre-treatment. Permanent Hypothyroidism: Risk is 10-20% in the first year, 5% per year thereafter, requiring lifelong LT4 replacement. Possibly a small increased lifetime risk of solid cancers.</li><li>\u2022 Radiation Thyroiditis: Mild pain may occur 1-2 weeks after treatment.</li><li>\u2022 Flare of Orbitopathy: Especially in smokers. Consider prednisone pre-treatment.</li><li>\u2022 Permanent Hypothyroidism: Risk is 10-20% in the first year, 5% per year thereafter, requiring lifelong LT4 replacement.</li><li>\u2022 Possibly a small increased lifetime risk of solid cancers.</li><li>\u2022 Contraindications: Pregnancy, breastfeeding and suspected thyroid cancer.</li><li>\u2022 Contraindications:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The full effect of RAI therapy for Graves' disease takes 2-3 months to manifest, which can explain persistent symptoms shortly after treatment.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "23f0163b",
      "audio": ""
    },
    {
      "text": "Which of the following is false regarding Hashimoto\u2019s thyroiditis?",
      "options": [
        {
          "label": "A",
          "text": "TPO and Tg antibodies in the mother can cause fetal hypothyroidism.",
          "correct": true
        },
        {
          "label": "B",
          "text": "High Iodine intake increases the risk.",
          "correct": false
        },
        {
          "label": "C",
          "text": "Thyroid destruction is primarily mediated by the CD8+ cytotoxic T cells.",
          "correct": false
        },
        {
          "label": "D",
          "text": "Alcohol intake is protective.",
          "correct": false
        }
      ],
      "correct_answer": "A. TPO and Tg antibodies in the mother can cause fetal hypothyroidism.",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) TPO and Tg antibodies in the mother can cause fetal hypothyroidism.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. High Iodine intake increases the risk: A high iodine or low selenium intake and decreased exposure to microorganisms in childhood increases risk.</li><li>\u2022 Option B. High Iodine intake increases the risk:</li><li>\u2022 Option C. Thyroid destruction is primarily mediated by the CD8+ cytotoxic T cells: True. Pathogenic effect of antibodies is restricted to a secondary role in amplifying an ongoing autoimmune response.</li><li>\u2022 Option C. Thyroid destruction is primarily mediated by the CD8+ cytotoxic T cells:</li><li>\u2022 Option D. Alcohol intake is protective: Smoking cessation transiently increases incidence, whereas alcohol intake seems protective.</li><li>\u2022 Option D. Alcohol intake is protective:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Transplacental passage of Tg or TPO antibodies has no effect on the fetal thyroid, whereas TSH-R blocking antibodies may induce transient neonatal hypothyroidism.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "1a1fd7a2",
      "audio": ""
    },
    {
      "text": "A 35-year-old woman presents with a one-week history of fever, neck pain, and fatigue. On physical examination, her thyroid gland is tender. Thyroid function tests reveal elevated free T4 and suppressed TSH. Which of the following statements regarding her underlying condition is FALSE?",
      "options": [
        {
          "label": "A",
          "text": "Associated with URI.",
          "correct": false
        },
        {
          "label": "B",
          "text": "Elevated ESR.",
          "correct": false
        },
        {
          "label": "C",
          "text": "Positive anti-TPO.",
          "correct": true
        },
        {
          "label": "D",
          "text": "Giant cells in biopsy.",
          "correct": false
        }
      ],
      "correct_answer": "C. Positive anti-TPO.",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Positive anti-TPO.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Associated with URI: This is a true statement, as De Quervain\u2019s thyroiditis is often triggered by a viral infection.</li><li>\u2022 Option</li><li>\u2022 A. Associated with URI:</li><li>\u2022 Option B. Elevated ESR: This is also true due to the inflammatory process.</li><li>\u2022 Option B. Elevated ESR:</li><li>\u2022 Option D. Giant cells in biopsy: This is the characteristic histological finding due to the presence of granulomas in De Quervain\u2019s thyroiditis.</li><li>\u2022 Option D. Giant cells in biopsy:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Thyroid peroxidase (TPO) antibodies are usually negative in subacute (De Quervain\u2019s) thyroiditis, which is associated with an elevated ESR and giant cells in biopsy following an upper respiratory infection.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "3f6455fa",
      "audio": ""
    },
    {
      "text": "A 30-year-old woman presents to her primary care physician 6 months after delivery with complaints of fatigue, cold intolerance, and weight gain for the last 3 weeks. She also reports feeling depressed and having difficulty concentrating. Her thyroid function tests reveal elevated TSH and low free T4 levels and positive anti-TPO antibodies. Which of the following is the most likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "De Quervain's thyroiditis",
          "correct": false
        },
        {
          "label": "B",
          "text": "Subacute lymphocytic thyroiditis",
          "correct": true
        },
        {
          "label": "C",
          "text": "Riedel's thyroiditis",
          "correct": false
        },
        {
          "label": "D",
          "text": "Hashimoto's thyroiditis",
          "correct": false
        }
      ],
      "correct_answer": "B. Subacute lymphocytic thyroiditis",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Subacute lymphocytic thyroiditis</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. De Quervain's thyroiditis: This is a painful form of thyroiditis and they have an elevated ESR. Anti TPO antibodies are rarely positive in De Quervain\u2019s.</li><li>\u2022 Option A. De Quervain's thyroiditis:</li><li>\u2022 Option C. Riedel's thyroiditis: This is a rare fibrotic thyroiditis with a hard, fixed goiter.</li><li>\u2022 Option C. Riedel's thyroiditis:</li><li>\u2022 Option D. Hashimoto's thyroiditis: While also autoimmune, Hashimoto's typically presents with a gradual (chronic) onset of hypothyroidism and is less likely to occur postpartum.</li><li>\u2022 Option D. Hashimoto's thyroiditis:</li><li>\u2022 Summary of post-partum thyroiditis:</li><li>\u2022 Summary of post-partum thyroiditis:</li><li>\u2022 Similar to De Quervain\u2019s thyroiditis, but painless and have normal ESR. Occurs in 5% of women 3-6 months postpartum, termed postpartum thyroiditis. Associated with TPO antibodies antepartum, 3x more common in type 1 diabetes. Recovery is the rule. Annual follow-up recommended as some develop permanent hypothyroidism. May recur in subsequent pregnancies.</li><li>\u2022 Similar to De Quervain\u2019s thyroiditis, but painless and have normal ESR.</li><li>\u2022 Occurs in 5% of women 3-6 months postpartum, termed postpartum thyroiditis.</li><li>\u2022 Associated with TPO antibodies antepartum, 3x more common in type 1 diabetes.</li><li>\u2022 Recovery is the rule. Annual follow-up recommended as some develop permanent hypothyroidism. May recur in subsequent pregnancies.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Subacute lymphocytic thyroiditis, also known as painless thyroiditis, often presents postpartum with a hypothyroid phase and positive anti-TPO antibodies.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "1e6f3260",
      "audio": ""
    },
    {
      "text": "A 35-year-old woman presents with a palpable thyroid nodule and has normal TSH levels. USG reveals a hypoechoic solid nodule with microcalcifications. Which of the following is the most appropriate next step in management?",
      "options": [
        {
          "label": "A",
          "text": "Observation and repeat USG in 6 months",
          "correct": false
        },
        {
          "label": "B",
          "text": "Fine needle aspiration biopsy (FNA)",
          "correct": true
        },
        {
          "label": "C",
          "text": "Radioiodine scanning",
          "correct": false
        },
        {
          "label": "D",
          "text": "Thyroid lobectomy",
          "correct": false
        }
      ],
      "correct_answer": "B. Fine needle aspiration biopsy (FNA)",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/17/screenshot-2024-08-17-142646_s0moNWZ.jpg"
      ],
      "explanation": "<p><strong>Ans. B) Fine needle aspiration biopsy (FNA)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Observation and repeat USG in 6 months: This approach is suitable for smaller or less suspicious nodules but not for those with high-risk features like microcalcifications. Delayed diagnosis could lead to potential complications if the nodule is malignant.</li><li>\u2022 Option A. Observation and repeat USG in 6 months:</li><li>\u2022 Option C. Radioiodine scanning: Useful only if hyperthyroid on TFTs.</li><li>\u2022 Option C. Radioiodine scanning:</li><li>\u2022 Option D. Thyroid lobectomy: Surgery is usually reserved for confirmed malignancy or large symptomatic nodules. FNA is required for diagnosis before considering surgery.</li><li>\u2022 Option D. Thyroid lobectomy:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Papillary thyroid cancer generally has a good prognosis, and its presence is not associated with a poor prognosis compared to other types of thyroid cancer.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "5ac1a835",
      "audio": ""
    },
    {
      "text": "A 30-year-old man is diagnosed with papillary thyroid carcinoma (PTC). Which of the following statements is not true?",
      "options": [
        {
          "label": "A",
          "text": "BRAF mutation is the most common genetic alteration",
          "correct": false
        },
        {
          "label": "B",
          "text": "Lymph node micrometastases indicates poor prognosis.",
          "correct": true
        },
        {
          "label": "C",
          "text": "It has a propensity to spread via the lymphatic system.",
          "correct": false
        },
        {
          "label": "D",
          "text": "PTC is present in up to 25% of thyroid glands at autopsy",
          "correct": false
        }
      ],
      "correct_answer": "B. Lymph node micrometastases indicates poor prognosis.",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Lymph node micrometastases indicates poor prognosis.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. BRAF mutation is the most common genetic alteration: True. a. BRAF V600E mutations reduce uptake of RAI and increase risk of recurrence (but effect on overall outcomes in unclear).</li><li>\u2022 Option A. BRAF mutation is the most common genetic alteration:</li><li>\u2022 Option C. It has a propensity to spread via the lymphatic system: This is true. PTC has a tendency to spread to the lymph nodes in the neck.</li><li>\u2022 Option C. It has a propensity to spread via the lymphatic system:</li><li>\u2022 Option D. PTC is present in up to 25% of thyroid glands at autopsy: This is also true. Many people have small, microscopic PTCs that never cause any problems.</li><li>\u2022 Option D. PTC is present in up to 25% of thyroid glands at autopsy:</li><li>\u2022 Summary if important thyroid cancers:</li><li>\u2022 Summary if important thyroid cancers:</li><li>\u2022 PTC: Most common type of thyroid cancer (80-85% of differentiated thyroid cancers) Genetics: RET/PTC rearrangements (20-40%), BRAF V600E mutation (most common), RAS mutations (20-30%).</li><li>\u2022 PTC: Most common type of thyroid cancer (80-85% of differentiated thyroid cancers) Genetics: RET/PTC rearrangements (20-40%), BRAF V600E mutation (most common), RAS mutations (20-30%).</li><li>\u2022 PTC:</li><li>\u2022 Genetics: RET/PTC rearrangements (20-40%), BRAF V600E mutation (most common), RAS mutations (20-30%).</li><li>\u2022 Genetics: RET/PTC rearrangements (20-40%), BRAF V600E mutation (most common), RAS mutations (20-30%).</li><li>\u2022 BRAF V600E mutations reduce uptake of RAI and increase risk of recurrence (but effect on overall outcomes in unclear).</li><li>\u2022 BRAF V600E mutations reduce uptake of RAI and increase risk of recurrence (but effect on overall outcomes in unclear).</li><li>\u2022 Microscopic PTC is found in \u223c 25% of autopsy thyroids (clinically insignificant). Characteristic cytological features: Orphan Annie eye appearance with Nuclear grooves and Prominent nucleoli. Tall cell, columnar cell, hobnail, poorly differentiated \u2013 aggressive variants. Can be multifocal & invade locally within the thyroid gland/ adjacent structures. Usually Spreads primarily via lymphatic system. Slow growth can lead to a significant burden of pulmonary metastases with few symptoms. Lymph node involvement is prognostic but micro metastases (< 2 mm) does not alter prognosis. Most PTCs are identified in early stages (I or II) with excellent prognosis. Stage IV disease has markedly increased mortality but is rare (~1%).</li><li>\u2022 Microscopic PTC is found in \u223c 25% of autopsy thyroids (clinically insignificant).</li><li>\u2022 Characteristic cytological features: Orphan Annie eye appearance with Nuclear grooves and Prominent nucleoli.</li><li>\u2022 Tall cell, columnar cell, hobnail, poorly differentiated \u2013 aggressive variants.</li><li>\u2022 Can be multifocal & invade locally within the thyroid gland/ adjacent structures.</li><li>\u2022 Usually Spreads primarily via lymphatic system.</li><li>\u2022 Slow growth can lead to a significant burden of pulmonary metastases with few symptoms.</li><li>\u2022 Lymph node involvement is prognostic but micro metastases (< 2 mm) does not alter prognosis. Most PTCs are identified in early stages (I or II) with excellent prognosis. Stage IV disease has markedly increased mortality but is rare (~1%).</li><li>\u2022 FTC: more common in iodine-deficient regions. Genetics: RAS mutations, PAX8-PPAR\u03b31 rearrangement. Diagnosis: Difficult by FNA alone, requires Bx to assess capsular/vascular invasion. Prognosis:</li><li>\u2022 FTC: more common in iodine-deficient regions. Genetics: RAS mutations, PAX8-PPAR\u03b31 rearrangement. Diagnosis: Difficult by FNA alone, requires Bx to assess capsular/vascular invasion. Prognosis:</li><li>\u2022 FTC:</li><li>\u2022 Genetics: RAS mutations, PAX8-PPAR\u03b31 rearrangement. Diagnosis: Difficult by FNA alone, requires Bx to assess capsular/vascular invasion. Prognosis:</li><li>\u2022 Genetics: RAS mutations, PAX8-PPAR\u03b31 rearrangement.</li><li>\u2022 Diagnosis: Difficult by FNA alone, requires Bx to assess capsular/vascular invasion.</li><li>\u2022 Prognosis:</li><li>\u2022 Capsular invasion only: Low risk of metastasis, lobectomy suffices. Angioinvasive FTC: More aggressive, can metastasize to bone, lung, and CNS.</li><li>\u2022 Capsular invasion only: Low risk of metastasis, lobectomy suffices.</li><li>\u2022 Angioinvasive FTC: More aggressive, can metastasize to bone, lung, and CNS.</li><li>\u2022 Higher mortality than PTC, partly due to more frequent stage IV presentation. Poor Prognostic Factors: Distant metastases, age >55 years, primary tumor size >4 cm, marked vascular invasion.</li><li>\u2022 Higher mortality than PTC, partly due to more frequent stage IV presentation.</li><li>\u2022 Poor Prognostic Factors: Distant metastases, age >55 years, primary tumor size >4 cm, marked vascular invasion.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Lymph node micrometastases (<2 mm) in papillary thyroid carcinoma (PTC) do not alter prognosis, even though lymph node involvement is prognostic.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "583075ad",
      "audio": ""
    },
    {
      "text": "Which of the following is false regarding thyroid cancer treatment after thyroidectomy?",
      "options": [
        {
          "label": "A",
          "text": "S. Tg is a sensitive marker post-surgery.",
          "correct": false
        },
        {
          "label": "B",
          "text": "Universal Target TSH post-surgery is 0.5-2 mIU/L.",
          "correct": true
        },
        {
          "label": "C",
          "text": "Patient should follow low Iodine diet for 1-2 weeks prior to I131 therapy.",
          "correct": false
        },
        {
          "label": "D",
          "text": "TSH > 25 is required at the time of I 131 therapy.",
          "correct": false
        }
      ],
      "correct_answer": "B. Universal Target TSH post-surgery is 0.5-2 mIU/L.",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Universal Target TSH post-surgery is 0.5-2 mIU/L.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. S. Tg is a sensitive marker post-surgery: This is true. Serum thyroglobulin (Tg) is a useful tumor marker for monitoring patients with papillary and follicular thyroid cancers after thyroidectomy.</li><li>\u2022 Option A. S. Tg is a sensitive marker post-surgery:</li><li>\u2022 Option C. Patient should follow low Iodine diet for 1-2 weeks prior to I131 therapy: This is also true. A low iodine diet is recommended before radioactive iodine (RAI) therapy to enhance the uptake of iodine by any remaining thyroid tissue or cancer cells.</li><li>\u2022 Option C. Patient should follow low Iodine diet for 1-2 weeks prior to I131 therapy:</li><li>\u2022 Option D. TSH > 25 is required at the time of I131 therapy: This is generally true for patients with high-risk thyroid cancer. A higher TSH level helps stimulate the uptake of RAI by thyroid cancer cells.</li><li>\u2022 Option D. TSH > 25 is required at the time of I131 therapy:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The target TSH level post-surgery for thyroid cancer patients is based on the risk of recurrence, not universally 0.5-2 mIU/L. It ranges from 0.5-2.0 mIU/L for low risk, 0.1-0.5 mIU/L for intermediate risk, to <0.1 mIU/L for high risk or metastatic disease.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "5fbd8f7f",
      "audio": ""
    },
    {
      "text": "A 60-year-old woman with chronic kidney disease presents with muscle cramps and tingling in her fingers. Her serum calcium is 7.7 mg/dL (normal: 8.5-10.5 mg/dL) and serum albumin is 3.0 g/dL (normal range: 3.5-5.0 g/dL). What is her corrected calcium level?",
      "options": [
        {
          "label": "A",
          "text": "8.0 mg/dL",
          "correct": false
        },
        {
          "label": "B",
          "text": "8.3 mg/dL",
          "correct": false
        },
        {
          "label": "C",
          "text": "8.5 mg/dL",
          "correct": true
        },
        {
          "label": "D",
          "text": "9.0 mg/dL",
          "correct": false
        }
      ],
      "correct_answer": "C. 8.5 mg/dL",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) 8.5 mg/dL</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Corrected calcium is calculated using the following formula:</li><li>\u2022 Corrected calcium (mg/dL) = Measured calcium (mg/dL) + 0.8 x (4.0 - Albumin [g/dL])</li><li>\u2022 In this case:</li><li>\u2022 Corrected calcium = 7.5 + 0.8 x (4.0 - 3.0) = 7.7 + 0.8 = 8.5 mg/dL</li><li>\u2022 Therefore, the patient's corrected calcium level is 8.5 mg/dL, which is within the normal range.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 To calculate the corrected calcium level in patients with low serum albumin, use the formula:</li><li>\u27a4 Corrected calcium (mg/dL) = Measured calcium (mg/dL) + 0.8 x (4.0 - Albumin [g/dL])</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "3ae8af71",
      "audio": ""
    },
    {
      "text": "A 60-year-old man with chronic alcoholism was started in IV dextrose. He develops cardiac arrhythmias, seizures, and rhabdomyolysis. Which of the following electrolyte disturbances is most likely responsible for her clinical deterioration?",
      "options": [
        {
          "label": "A",
          "text": "Hypernatremia",
          "correct": false
        },
        {
          "label": "B",
          "text": "Hypocalcemia",
          "correct": false
        },
        {
          "label": "C",
          "text": "Hyperphosphatemia",
          "correct": false
        },
        {
          "label": "D",
          "text": "Hypophosphatemia",
          "correct": true
        }
      ],
      "correct_answer": "D. Hypophosphatemia",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Hypophosphatemia</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Hypernatremia: Hypernatremia (high sodium) is not a typical feature of refeeding syndrome.</li><li>\u2022 Option A. Hypernatremia:</li><li>\u2022 Option B. Hypocalcemia: Hypocalcemia (low calcium) can occur in refeeding syndrome, but it is less common and less severe than hypophosphatemia.</li><li>\u2022 Option B. Hypocalcemia:</li><li>\u2022 Option C. Hyperphosphatemia: Hyperphosphatemia (high phosphate) is the opposite of what is seen in refeeding syndrome.</li><li>\u2022 Option C. Hyperphosphatemia:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Refeeding syndrome, commonly occurring in severely malnourished individuals after reintroducing nutrition, is characterized by hypophosphatemia, which can lead to cardiac arrhythmias, seizures, and rhabdomyolysis.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "a8a9eac4",
      "audio": ""
    },
    {
      "text": "Which of the following monoclonal antibodies has been approved for X-linked hypophosphatemia (XLH)?",
      "options": [
        {
          "label": "A",
          "text": "Burosumab",
          "correct": true
        },
        {
          "label": "B",
          "text": "Teplizumab",
          "correct": false
        },
        {
          "label": "C",
          "text": "Teprotumumab",
          "correct": false
        },
        {
          "label": "D",
          "text": "Atezolizumab",
          "correct": false
        }
      ],
      "correct_answer": "A. Burosumab",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Burosumab</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Teplizumab: This monoclonal antibody (CD3) is used in the treatment of type 1 diabetes.</li><li>\u2022 Option B. Teplizumab:</li><li>\u2022 Option C. Teprotumumab: This monoclonal antibody (IGF-1r) is used in the treatment of thyroid eye disease (Graves' ophthalmopathy).</li><li>\u2022 Option C. Teprotumumab:</li><li>\u2022 Option D. Atezolizumab: This monoclonal antibody (PD-L1) is used in the treatment of certain types of cancer.</li><li>\u2022 Option D. Atezolizumab:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Burosumab is a monoclonal antibody approved for X-linked hypophosphatemia (XLH).</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "65a4199d",
      "audio": ""
    },
    {
      "text": "Which of the following stimulates the production of 1,25(OH)2D (Calcitriol) by activating 1\u03b1-hydroxylase in the kidneys?",
      "options": [
        {
          "label": "A",
          "text": "PTH (Parathyroid Hormone)",
          "correct": true
        },
        {
          "label": "B",
          "text": "Calcium",
          "correct": false
        },
        {
          "label": "C",
          "text": "FGF-23 (Fibroblast Growth Factor 23)",
          "correct": false
        },
        {
          "label": "D",
          "text": "1,25 (OH)2D (Calcitriol)",
          "correct": false
        }
      ],
      "correct_answer": "A. PTH (Parathyroid Hormone)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) PTH (Parathyroid Hormone)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Calcium: High calcium levels actually suppress 1\u03b1-hydroxylase activity, decreasing calcitriol production.</li><li>\u2022 Option B. Calcium:</li><li>\u2022 Option C. FGF-23: FGF-23 also suppresses 1\u03b1-hydroxylase activity and reduces calcitriol levels.</li><li>\u2022 Option C. FGF-23:</li><li>\u2022 Option D. 1,25 (OH)2D (Calcitriol): Calcitriol acts through a negative feedback loop to inhibit its own production by suppressing 1\u03b1-hydroxylase.</li><li>\u2022 Option D. 1,25 (OH)2D (Calcitriol):</li><li>\u2022 Summary:</li><li>\u2022 Summary:</li><li>\u2022 Vitamin D basics:</li><li>\u2022 Vitamin D basics:</li><li>\u2022 Cutaneous production of cholecalciferol is reduced by melanin and sunblocks. 25 (OH)D [calcidiol] is the major circulating form (formed in the liver by 25 hydroxylase). t1/2 \u223c 2-3 weeks (88% of 25 (OH)D is bound to Vitamin D binding protein) 2nd hydroxylation occurs in kidney (PCT) by 1\u03b1-hydroxylase forming 1,25 (OH)2D (Calcitriol) \u2013 the active from. 1\u03b1-hydroxylase is hormonally regulated \u2013 Stimulated by: PTH and low phosphate. Inhibited by: Ca, FGF-23 & 1,25 (OH)2D (Calcitriol). 1\u03b1-hydroxylase is also present in other cells (keratinocytes, placenta, macrophages), but not hormonally regulated. Inactivation of vitamin D metabolites occurs through 24-hydroxylation.</li><li>\u2022 Cutaneous production of cholecalciferol is reduced by melanin and sunblocks.</li><li>\u2022 25 (OH)D [calcidiol] is the major circulating form (formed in the liver by 25 hydroxylase). t1/2 \u223c 2-3 weeks (88% of 25 (OH)D is bound to Vitamin D binding protein)</li><li>\u2022 2nd hydroxylation occurs in kidney (PCT) by 1\u03b1-hydroxylase forming 1,25 (OH)2D (Calcitriol) \u2013 the active from. 1\u03b1-hydroxylase is hormonally regulated \u2013 Stimulated by: PTH and low phosphate. Inhibited by: Ca, FGF-23 & 1,25 (OH)2D (Calcitriol).</li><li>\u2022 Stimulated by: PTH and low phosphate. Inhibited by: Ca, FGF-23 & 1,25 (OH)2D (Calcitriol).</li><li>\u2022 Stimulated by: PTH and low phosphate.</li><li>\u2022 Inhibited by: Ca, FGF-23 & 1,25 (OH)2D (Calcitriol).</li><li>\u2022 1\u03b1-hydroxylase is also present in other cells (keratinocytes, placenta, macrophages), but not hormonally regulated.</li><li>\u2022 Inactivation of vitamin D metabolites occurs through 24-hydroxylation.</li><li>\u2022 Actions of 1,25(OH)2D [calcitriol]:</li><li>\u2022 Actions of 1,25(OH)2D [calcitriol]:</li><li>\u2022 VDR forms heterodimer with retinoid X receptor, inducing target gene expression. VDR is expressed in various cells and tissues. Effects of VDR - Intestine: Increased calcium absorption by inducing calbindin 9K, TRPV5, TRPV6. Bone: Regulates osteoblasts (increases osteocalcin, osteopontin, RANKL and FGF23). Parathyroid: Reduces PTH production. Others: Antiproliferative effects (keratinocytes, breast ca cells, prostate ca cells). Effects of VDR on hair follicle is ligand (Vitamin D) independent!!</li><li>\u2022 VDR forms heterodimer with retinoid X receptor, inducing target gene expression.</li><li>\u2022 VDR is expressed in various cells and tissues. Effects of VDR - Intestine: Increased calcium absorption by inducing calbindin 9K, TRPV5, TRPV6. Bone: Regulates osteoblasts (increases osteocalcin, osteopontin, RANKL and FGF23). Parathyroid: Reduces PTH production. Others: Antiproliferative effects (keratinocytes, breast ca cells, prostate ca cells). Effects of VDR on hair follicle is ligand (Vitamin D) independent!!</li><li>\u2022 Intestine: Increased calcium absorption by inducing calbindin 9K, TRPV5, TRPV6. Bone: Regulates osteoblasts (increases osteocalcin, osteopontin, RANKL and FGF23). Parathyroid: Reduces PTH production. Others: Antiproliferative effects (keratinocytes, breast ca cells, prostate ca cells). Effects of VDR on hair follicle is ligand (Vitamin D) independent!!</li><li>\u2022 Intestine: Increased calcium absorption by inducing calbindin 9K, TRPV5, TRPV6.</li><li>\u2022 Bone: Regulates osteoblasts (increases osteocalcin, osteopontin, RANKL and FGF23).</li><li>\u2022 Parathyroid: Reduces PTH production.</li><li>\u2022 Others: Antiproliferative effects (keratinocytes, breast ca cells, prostate ca cells).</li><li>\u2022 Effects of VDR on hair follicle is ligand (Vitamin D) independent!!</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 PTH (Parathyroid Hormone) stimulates the production of 1,25(OH)2D (Calcitriol) by activating 1\u03b1-hydroxylase in the kidneys.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "c0df7a1a",
      "audio": ""
    },
    {
      "text": "A patient presents with fatigue and bone pain. Laboratory findings reveal low serum calcium, elevated parathyroid hormone (PTH), and low 25-hydroxyvitamin D [calcidiol] levels. Which of the following statements regarding this patient's condition is incorrect?",
      "options": [
        {
          "label": "A",
          "text": "1,25 (OH)2 D [calcitriol] levels are often normal.",
          "correct": false
        },
        {
          "label": "B",
          "text": "Expansion of the proliferating zone is seen in rickets.",
          "correct": true
        },
        {
          "label": "C",
          "text": "Looser's zones seen in osteomalacia occur near large arteries.",
          "correct": false
        },
        {
          "label": "D",
          "text": "Proximal myopathy can occur.",
          "correct": false
        }
      ],
      "correct_answer": "B. Expansion of the proliferating zone is seen in rickets.",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Expansion of the proliferating zone is seen in rickets.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. 1,25 (OH)2 D (calcitriol) levels are often normal: In severe vitamin D deficiency, there is a compensatory increase in PTH, which stimulates 1\u03b1-hydroxylase activity and can maintain normal calcitriol levels despite the deficiency.</li><li>\u2022 Option A. 1,25 (OH)2 D (calcitriol) levels are often normal:</li><li>\u2022 Option C. Looser's zones seen in osteomalacia occur near large arteries: These radiolucent lines, also known as pseudofractures, are characteristic of osteomalacia and are often found adjacent to large arteries. These are often long, but only a few mm wide and common in scapula, pelvis and femoral neck.</li><li>\u2022 Option C. Looser's zones seen in osteomalacia occur near large arteries:</li><li>\u2022 Option D. Proximal myopathy can occur: Muscle weakness, particularly in the proximal muscles, is a common symptom of severe vitamin D deficiency.</li><li>\u2022 Option D. Proximal myopathy can occur:</li><li>\u2022 Summary: Vitamin D deficiency \u2013</li><li>\u2022 Summary: Vitamin D deficiency \u2013</li><li>\u2022 Causes: Poor sunlight exposure, poor intake/malabsorption, increased demand (barbiturates, phenytoin, rifampin, nephrotic syndrome), impaired activation (liver or kidney disease, hypoparathyroidism, FGF23 excess) or resistance (VDR mutations). Genetic causes: VDDR type I (1\u03b1-hydroxylase mutations, can be responsive to calcitriol) & VDDR type 2 (VDR mutations, has alopecia and resistant to calcitriol). Clinical Manifestations: \u2193 S.Ca, \u2191 PTH (leading to \u2193PO4 and \u2191ALP), proximal myopathy, and increased CV mortality. Rickets in children before epiphyseal fusion. Osteomalacia in adults. Diagnosis: Serum 25(OH)D level \u2013 best screening test. Vitamin D sufficiency is defined as >50 nmol/L (>20 ng/mL). <37 nmol/L (<15 ng/mL) \u2013 can lead to \u2191 PTH & \u2191 ALP. Treatment: RDA: 600 IU/d (1-70 years) and 800 IU/d (>70 years). But up to 40000 IU/d is safe ! Severe deficiency: Repletion (50000 IU/week for 3-12 weeks) followed by maintenance therapy (800 IU/d). If 1\u03b1-hydroxylation is defective, use metabolites not requiring activation (calcitriol, doxercalciferol, alfacalcidol). Monitor treatment with serum and urinary calcium measurements. Target 24-h urinary Ca = 100\u2013250 mg/d (> 250mg/d should lead to reduction in dosage).</li><li>\u2022 Causes: Poor sunlight exposure, poor intake/malabsorption, increased demand (barbiturates, phenytoin, rifampin, nephrotic syndrome), impaired activation (liver or kidney disease, hypoparathyroidism, FGF23 excess) or resistance (VDR mutations). Genetic causes: VDDR type I (1\u03b1-hydroxylase mutations, can be responsive to calcitriol) & VDDR type 2 (VDR mutations, has alopecia and resistant to calcitriol).</li><li>\u2022 Causes:</li><li>\u2022 Genetic causes: VDDR type I (1\u03b1-hydroxylase mutations, can be responsive to calcitriol) & VDDR type 2 (VDR mutations, has alopecia and resistant to calcitriol).</li><li>\u2022 Genetic causes: VDDR type I (1\u03b1-hydroxylase mutations, can be responsive to calcitriol) & VDDR type 2 (VDR mutations, has alopecia and resistant to calcitriol).</li><li>\u2022 Clinical Manifestations: \u2193 S.Ca, \u2191 PTH (leading to \u2193PO4 and \u2191ALP), proximal myopathy, and increased CV mortality. Rickets in children before epiphyseal fusion. Osteomalacia in adults.</li><li>\u2022 Clinical Manifestations:</li><li>\u2022 Rickets in children before epiphyseal fusion. Osteomalacia in adults.</li><li>\u2022 Rickets in children before epiphyseal fusion.</li><li>\u2022 Osteomalacia in adults.</li><li>\u2022 Diagnosis: Serum 25(OH)D level \u2013 best screening test. Vitamin D sufficiency is defined as >50 nmol/L (>20 ng/mL). <37 nmol/L (<15 ng/mL) \u2013 can lead to \u2191 PTH & \u2191 ALP.</li><li>\u2022 Diagnosis:</li><li>\u2022 Vitamin D sufficiency is defined as >50 nmol/L (>20 ng/mL). <37 nmol/L (<15 ng/mL) \u2013 can lead to \u2191 PTH & \u2191 ALP.</li><li>\u2022 Vitamin D sufficiency is defined as >50 nmol/L (>20 ng/mL).</li><li>\u2022 <37 nmol/L (<15 ng/mL) \u2013 can lead to \u2191 PTH & \u2191 ALP.</li><li>\u2022 Treatment: RDA: 600 IU/d (1-70 years) and 800 IU/d (>70 years). But up to 40000 IU/d is safe ! Severe deficiency: Repletion (50000 IU/week for 3-12 weeks) followed by maintenance therapy (800 IU/d). If 1\u03b1-hydroxylation is defective, use metabolites not requiring activation (calcitriol, doxercalciferol, alfacalcidol). Monitor treatment with serum and urinary calcium measurements. Target 24-h urinary Ca = 100\u2013250 mg/d (> 250mg/d should lead to reduction in dosage).</li><li>\u2022 Treatment:</li><li>\u2022 RDA: 600 IU/d (1-70 years) and 800 IU/d (>70 years). But up to 40000 IU/d is safe ! Severe deficiency: Repletion (50000 IU/week for 3-12 weeks) followed by maintenance therapy (800 IU/d). If 1\u03b1-hydroxylation is defective, use metabolites not requiring activation (calcitriol, doxercalciferol, alfacalcidol). Monitor treatment with serum and urinary calcium measurements. Target 24-h urinary Ca = 100\u2013250 mg/d (> 250mg/d should lead to reduction in dosage).</li><li>\u2022 RDA: 600 IU/d (1-70 years) and 800 IU/d (>70 years). But up to 40000 IU/d is safe !</li><li>\u2022 Severe deficiency: Repletion (50000 IU/week for 3-12 weeks) followed by maintenance therapy (800 IU/d).</li><li>\u2022 If 1\u03b1-hydroxylation is defective, use metabolites not requiring activation (calcitriol, doxercalciferol, alfacalcidol).</li><li>\u2022 Monitor treatment with serum and urinary calcium measurements. Target 24-h urinary Ca = 100\u2013250 mg/d (> 250mg/d should lead to reduction in dosage).</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Expansion of the proliferating zone is not seen in rickets; it is the hypertrophic zone that is expanded.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "3a563364",
      "audio": ""
    },
    {
      "text": "Which of the following genetic mutations is usually associated with parathyroid carcinoma?",
      "options": [
        {
          "label": "A",
          "text": "MEN1",
          "correct": false
        },
        {
          "label": "B",
          "text": "HRPT2",
          "correct": true
        },
        {
          "label": "C",
          "text": "CASR",
          "correct": false
        },
        {
          "label": "D",
          "text": "GCM2",
          "correct": false
        }
      ],
      "correct_answer": "B. HRPT2",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) HRPT2</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. MEN1: Mutations in this gene are associated with multiple endocrine neoplasia type 1 (MEN1), a syndrome that can include parathyroid adenomas but rarely carcinoma.</li><li>\u2022 Option A. MEN1:</li><li>\u2022 Option C. CASR: Mutations in this gene cause familial hypocalciuric hypercalcemia (FHH), a benign condition unrelated to parathyroid cancer.</li><li>\u2022 Option C. CASR:</li><li>\u2022 Option D. GCM2: Mutations in this gene are associated with non-syndromic familial isolated hyperparathyroidism (FIHP), which is characterized by benign parathyroid tumors.</li><li>\u2022 Option D. GCM2:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 HRPT2 mutations are usually associated with parathyroid carcinoma.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "5fa4ef23",
      "audio": ""
    },
    {
      "text": "A 43-year-old male presents with a serum calcium of 11.2 mg/dL (normal 8.5-10.5) and a parathyroid hormone (PTH) level of 110 pg/mL (normal 15-70 pg/mL). He is otherwise asymptomatic, has normal renal function, and his dual-energy X-ray absorptiometry (DXA) scan is within normal limits. What is the most appropriate management?",
      "options": [
        {
          "label": "A",
          "text": "Observation",
          "correct": false
        },
        {
          "label": "B",
          "text": "Parathyroidectomy",
          "correct": true
        },
        {
          "label": "C",
          "text": "Cinacalcet",
          "correct": false
        },
        {
          "label": "D",
          "text": "Bisphosphonates",
          "correct": false
        }
      ],
      "correct_answer": "B. Parathyroidectomy",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Parathyroidectomy</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Observation: While observation might be considered in elderly patients with mild PHPT, it is not appropriate for a young, asymptomatic patient with elevated S.Ca levels.</li><li>\u2022 Option A. Observation:</li><li>\u2022 Option C. Cinacalcet: Cinacalcet is a calcimimetic that can lower PTH and calcium levels. However, it is not a first-line treatment for PHPT and is generally reserved for patients who are not surgical candidates or who have persistent PHPT post-surgery.</li><li>\u2022 Option C. Cinacalcet:</li><li>\u2022 Option D. Bisphosphonates: Bisphosphonates can help to prevent bone loss but do not address the underlying cause of hyperparathyroidism, which is excessive PTH secretion.</li><li>\u2022 Option D. Bisphosphonates:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The most appropriate management for a 43-year-old male with primary hyperparathyroidism (PHPT), elevated serum calcium, and PTH levels is parathyroidectomy .</li><li>\u27a4 parathyroidectomy</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "4fa803fb",
      "audio": ""
    },
    {
      "text": "A 64-year-old female with PHPT underwent parathyroidectomy. On POD 4, she experiences persistent hypocalcemia with low PTH levels, requiring continuous IV calcium infusion to maintain S.Ca. Which of the following is the most appropriate next step?",
      "options": [
        {
          "label": "A",
          "text": "Neck exploration under general anesthesia.",
          "correct": false
        },
        {
          "label": "B",
          "text": "Check Mg levels.",
          "correct": true
        },
        {
          "label": "C",
          "text": "Neck Ultrasound to look for parathyroids.",
          "correct": false
        },
        {
          "label": "D",
          "text": "Add Cinacalcet.",
          "correct": false
        }
      ],
      "correct_answer": "B. Check Mg levels.",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Check Mg levels.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Neck exploration under general anesthesia: This is invasive and usually done if there is persistent hyperparathyroidism.</li><li>\u2022 Option A. Neck exploration under general anesthesia:</li><li>\u2022 Option C. Neck Ultrasound to look for parathyroids: Will not be providing any useful information in a post-op patient with hypoparathyroidism.</li><li>\u2022 Option C. Neck Ultrasound to look for parathyroids:</li><li>\u2022 Option D. Add Cinacalcet: Cinacalcet is a calcimimetic that lowers PTH, which is already low in this patient. It would be inappropriate and potentially worsen hypocalcemia.</li><li>\u2022 Option D. Add Cinacalcet:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 In a patient who has persistent hypocalcemia and low PTH levels post-parathyroidectomy, the most appropriate next step is to check magnesium levels .</li><li>\u27a4 check magnesium levels</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "0061ef10",
      "audio": ""
    }
  ]
}